Posted on

MES and QMS in Pharma: What’s the Real Difference?

Difference between MES and QMS in Pharma

If you work in pharmaceutical manufacturing, you’ve probably heard both terms tossed around in the same meeting, sometimes even used interchangeably. However, MES and QMS are not the same.

Why MES and QMS in Pharma Matters

The reason why MES and QMS in pharma matter is that these two systems solve different problems, even when they work alongside each other within the same manufacturing facility.

Let us put it simply: MES manages and records manufacturing execution at the shop-floor level, while QMS governs the broader quality processes required to maintain product quality, compliance and continual improvement.

It is also important to recognise that MES is generally a digital manufacturing application, while a QMS is the wider quality-management framework of an organisation. A QMS may be supported by electronic quality management software, commonly referred to as eQMS, but it is not limited to software alone.

Unclear system boundaries can result in duplicated workflows, disconnected records, incomplete traceability and gaps in validation. Understanding the role of each system is therefore important when planning pharmaceutical operations and digital infrastructure.

The ISA-95 framework places MES within manufacturing operations management, between enterprise-level business systems and lower-level plant automation and control systems. ICH Q10, in contrast, describes the broader pharmaceutical quality system across the product lifecycle. 

What Is an MES System in Pharmaceutical Manufacturing?

A MES system in pharmaceutical manufacturing is software that operates between the plant floor and the enterprise resource planning (ERP) layer. It follows manufacturing activities as they occur on the production floor.

Imagine it as the nervous system of a manufacturing plant. It gathers data from equipment, operators, and materials in real time, then exchanges relevant data with enterprise applications and plant-floor automation systems.

This is what an MES usually does:

  • Electronic batch records (EBR): replacing or supplementing paper batch records
  • Managing the recipes, formulas and manufacturing instructions for each production run
  • Monitoring equipment status and enforcing defined manufacturing-workflow requirements
  • Material genealogy, to trace every ingredient to its source
  • Scheduling and dispatching of work orders on the floor
  • Recording and escalating manufacturing exceptions when a process departs from defined limits

Depending on the application’s scope and configuration, an MES may also support operator identification, electronic signatures, material-status checks and connections with ERP, LIMS and quality systems.

A manufacturing execution system is designed to capture and analyse data in real time and ensure that every step of the manufacturing process complies with good manufacturing practices and regulatory requirements, such as FDA 21 CFR Part 11, where the system creates or maintains regulated electronic records.
However, Part 11 does not apply simply because a system is called MES. Its applicability depends on whether electronic records and electronic signatures are being used to meet requirements under applicable FDA regulations.
That last point is important. And in pharma, a MES is more than efficiency. It is about proving with a record that is held digitally that each batch was produced the way it was supposed to be produced.
FDA requirements call for complete production and control records for every drug-product batch, but they do not require manufacturers to use a software application specifically called MES. 

What Is a QMS in Pharma?

A Quality Management System (QMS) is the system that governs how a company manages quality across the whole company, not just on the production line. This includes documentation, training records, deviations, complaints, audits, corrective and preventive actions (CAPA), and supplier qualification, change control, management review and continual improvement..

MES is at the plant floor level, while QMS spans the entire enterprise. It answers questions such as these.

  • Was this deviation properly investigated and closed out?
  • Are all standard operating procedures up to date and approved?
  • Is every employee trained on the most recent version of a document?
  • Was the right root cause analysis triggered by a customer complaint?
  • Was a change evaluated for its potential effect on product quality, validation and regulatory compliance?
  • Was the effectiveness of a corrective or preventive action evaluated?

A QMS aligned with a framework such as ICH Q10 provides leadership visibility into whether the quality system itself is working, not just whether one batch passed inspection.
ICH Q10 describes a pharmaceutical quality-system model that includes process-performance and product-quality monitoring, CAPA, change management and management review. 

MES and QMS in Pharma: The Core Difference

MES and QMS in Pharma: The Core Difference

Here is the easiest way to differentiate between them:

  1. Manufacturing execution is managed and recorded through MES. It monitors what happens during manufacturing, step by step, in real or near-real time.
  2. QMS governs the wider quality processes. It manages quality events, procedures, investigations, approvals, corrective actions and continual improvement.
  3. An MES asks: Did this batch follow the approved recipe, and can I prove it?
  4. A QMS asks: “Is our quality system adequate overall, and are quality events being appropriately managed and resolved?”

Both systems can contain records that regulators will want to see during an inspection. Neither substitutes for the other.

However, QMS should not be viewed only as a software application. A pharmaceutical quality system also includes people, responsibilities, procedures, governance and management oversight. 

Why Integration Between MES and QMS Matters

Challenges arise when these two systems do not communicate with each other.
When MES and QMS are disconnected, teams may have to manually transfer manufacturing information into quality workflows. This can create delayed deviation reporting, duplicate data entry, inconsistent records and incomplete links between batch information and quality investigations.

This is a familiar story throughout the industry. MES is positioned within manufacturing operations management under the ISA-95 framework.
Vendors are increasingly developing unified platforms where MES and QMS share data rather than being separate silos. If there is a deviation on the line, an integrated system can initiate or provide information to a quality event, depending on the approved workflow and configured business rules, rather than relying on someone to see it and log it manually later.
Not every equipment alarm or process exception should automatically become a formal quality deviation. The company must define which events require quality assessment, which system owns each record and how the connected workflow will be reviewed and validated.

ISA-95 provides models and terminology for defining system boundaries and information exchanges between manufacturing-control and enterprise functions. 

This integration is not just a software choice for a facility. It changes how the plant is built from the ground up, how sensors are placed, how data moves from one system to another, and how validation is planned during construction. It may also affect equipment connectivity, instrumentation, OT networks, operator terminals, data ownership, cybersecurity and system-interface requirements. That’s the world of facility design and engineering, well before any software vendors are called in.”

How Facility Design Shapes MES and QMS Success

How Facility Design Shapes MES and QMS Success

It’s a common mistake to think of MES and QMS as IT systems that can simply be added after the facility is built. It turns out that the engineering of a plant has a direct impact on how easily MES and other production-related systems can be connected and implemented later.

If equipment, utilities, and cleanroom layouts are not designed with data capture and traceability in mind, teams have to retrofit sensors and workarounds after the fact. That adds cost and leaves holes in the traceability that MES is supposed to provide.

However, the effectiveness of a QMS depends not only on facility design but also on quality governance, procedures, responsibilities, training, system ownership, change management and management oversight. 

This is where a company such as Pharma Access comes into the picture.

Pharma Access is a turnkey pharmaceutical engineering partner offering engineering design, construction & installation, and commissioning, qualification & validation (CQV) for manufacturing facilities. Their project management & EPCMV services are focused on taking a facility from concept to operational readiness, which includes planning for the automation and data infrastructure that MES and QMS rely on later.
During concept, basic and detailed design, Pharma Access can support the engineering foundations needed for future digital-manufacturing systems. These may include equipment interfaces, instrumentation, OT infrastructure, utility monitoring, operator-access points, data pathways and validation responsibilities, depending on the agreed project scope.
The move to full digital traceability is a much easier process when a facility’s electrical, instrumentation, automation and cleanroom is built around these systems from day one.

This does not imply that Pharma Access supplies or configures MES or QMS software unless those activities are specifically included within its service scope.

EU GMP Annex 11 places computerised systems within the pharmaceutical quality system and addresses lifecycle risk management, validation and the qualification of IT infrastructure.

Practical Steps to Align MES and QMS in a Pharma Facility

Identify quality-critical process steps before selecting software.

  1. Determine what data should automatically flow from MES to QMS, such as deviations and manufacturing exceptions, nonconformances, batch holds and investigation references.
    Laboratory out-of-specification results are generally managed through laboratory and quality processes. Where LIMS is used, the required interfaces among LIMS, MES and QMS should also be defined. 
  2. Involve engineering and facility design teams early—not after equipment is in place Quality, manufacturing, IT, automation, engineering and validation teams should agree on system boundaries and infrastructure requirements before the design is finalised. .
  3. Test the integration, not just each system in isolation, Testing should confirm data mapping, timestamps, electronic signatures, record ownership, audit trails, exception handling and system recovery across the connected applications..
  4. Train operators on how the two systems work together so that a batch record and a quality event are never two separate stories.

If any of these steps are not performed, it usually manifests later as a data gap during an audit and is much more expensive to fix than to plan for in the first place.
WHO data-integrity guidance addresses data governance, data transfer, training, good documentation practices and controls for computerised systems. 

Regulatory Weight Behind Both Systems

MES and QMS are both of regulatory importance, but from different perspectives. FDA’s 21 CFR Part 11 covers electronic records and signatures, which are applicable where MES-generated electronic records or electronic signatures are used to meet requirements under applicable FDA regulations. Quality system regulations, in contrast, require a documented, auditable QMS that spans the life of the product, from raw material intake to post-market complaints.

Inspectors do not ask which system is ‘more important’. They assess whether the available records and quality processes demonstrate that a product was made safely, consistently, and in accordance with approved procedures? That proof only holds up if the shop floor data and the quality department data tell the same story.

For facilities supplying European markets, EU GMP Annex 11 should also be considered for GMP-relevant computerised systems. The current Annex 11 remains available through EudraLex Volume 4, while the European Commission has also undertaken consultation on proposed revisions.

Final Thoughts

MES and QMS in pharma are not competing systems. They are two sides of the same compliance and quality coin. In pharmaceuticals, real- or near-real-time visibility into and management of manufacturing execution, while a QMS provides the broader framework that keeps that process accountable.
Direct control of equipment and process conditions generally remains within equipment-control, PLC, DCS or SCADA systems. 

The meeting of the two starts long before software implementation. It starts with how a facility is designed, wired, and validated. This is why companies that are planning new or upgraded facilities often bring in experienced engineering partners early in the process, as retrofitting data infrastructure after construction is much more difficult than planning for it from the start.
A QMS is fundamental to pharmaceutical quality governance. MES, by comparison, is a technology choice that can strengthen manufacturing execution, electronic traceability and data availability, but it is not mandated by name. 

Frequently Asked Questions

1. What is the main difference between MES and QMS in pharma? 

MES handles production data in real time, batch records, and equipment tracking on the shop floor. QMS provides you with the overall quality framework, including deviations, CAPA, training records, and document control across the entire company.MES manages and records manufacturing execution, while QMS governs the processes through which quality is managed, investigated and improved. 

2. Can a pharma company use MES without a QMS, or vice versa? 

A pharmaceutical company can operate without a software application specifically called MES, provided it maintains appropriate manufacturing controls, records, traceability, review and data-integrity measures. Without a QMS, there’s no framework for managing deviations and corrective actions. Without MES, a company may use controlled paper records, another validated electronic application or an appropriately managed hybrid system. MES is not the only method of maintaining batch records and traceability.

3. Why should MES and QMS be integrated in pharmaceutical manufacturing? 

With integration, quality events can be initiated or supported using relevant production data, according to approved workflows and business rules. This fills gaps in traceability and speeds up finding and investigating deviations.Integration can also reduce duplicate data entry and improve the connection between manufacturing records and quality investigations. 

4. Does facility design really affect how well MES and QMS perform later? 

Yes. If sensors, utilities, and data infrastructure are not part of the facility design, teams are forced to retrofit systems after construction, which is costlier and often leads to gaps in traceability.This is particularly relevant to MES and its connections with equipment and automation systems. QMS performance also depends heavily on quality governance, procedures, training, system ownership and management oversight. 

5. Who should be involved when planning MES and QMS for a new pharma facility? 

Involve quality teams, IT, automation engineers, and the facility design or EPCMV partner early on. Manufacturing operations, validation, QC or laboratory representatives and equipment suppliers may also need to participate, depending on the project scope. Having these groups plan together from the start avoids costly rework later in the project.

Posted on

Pharmaceutical Patents Expiring in FY2026–27: Manufacturing Readiness Beyond the Patent Date

Pharmaceutical Patents Expiring in FY2026–27: Manufacturing Readiness Beyond the Patent Date

Research cut-off date: 14 July 2026
Primary jurisdiction: United States
Fiscal-year period reviewed: 1 April 2026 to 31 March 2027

Pharmaceutical patent expiries in FY2026–27 may help generic manufacturers, API producers, CDMOs and facility owners identify products for further evaluation. However, a patent date should not be treated as a confirmed generic-launch date.

A pharmaceutical product may be protected by multiple patents covering the active ingredient, formulation, crystal form, manufacturing process, dosage regimen, indication or delivery device. Regulatory exclusivity, pediatric exclusivity, patent-term extensions, litigation, settlements and first-applicant exclusivity may also affect commercial entry.

For manufacturers, patent screening is therefore only the starting point. A viable programme must also consider regulatory approval, API availability, formulation development, process complexity, containment, equipment lead times, capacity, technology transfer, validation and GMP infrastructure.

Pharma Access supports pharmaceutical companies in translating a verified product strategy into practical manufacturing requirements. This may involve assessing an existing facility, adding a new production line, expanding a brownfield site or developing a greenfield plant.

Looking for verified patent and regulatory references without reading the full article? Jump straight to the Source Register.

Understanding Patent Expiry and Loss of Exclusivity

Patent expiry is the end of one patent in a defined jurisdiction. It does not necessarily mean that all protection for the product has ended.

Regulatory exclusivity is separate from patent protection and may prevent competing applications from being submitted or approved for a defined period. Loss of exclusivity, or LOE, is a broader commercial term that may refer to the end of a key patent, regulatory exclusivity, pediatric exclusivity, a settlement date or the expected start of generic competition.

The FDA Orange Book identifies approved drug products together with associated U.S. patent and regulatory-exclusivity information. Even when one listed patent expires, market entry may still depend on later patents, litigation, settlement terms, ANDA status, labelling strategy and 180-day exclusivity.

Pharmaceutical Products Facing Patent Milestones in FY2026–27

Eliquis — Apixaban

Eliquis is an oral anticoagulant marketed by Bristol Myers Squibb and Pfizer. An FDA tentative-approval letter identifies U.S. Patent 6,967,208 with an expiry date of 21 November 2026, while another listed patent continues to 24 February 2031.

Bristol Myers Squibb identifies 2028 as its estimated minimum U.S. market-exclusivity date and states that certain settled generic companies may launch in 2028, subject to additional challenges. The November 2026 date should therefore be treated as one patent milestone, not the end of all U.S. protection.

For manufacturers, apixaban may still be relevant to API and oral-solid-dose capacity planning. Investment decisions should be linked to the target jurisdiction, legal pathway, regulatory status, supply strategy and expected entry arrangements.

Ibrance — Palbociclib

Ibrance is an oral CDK4/6 inhibitor marketed by Pfizer. Pfizer reported that a U.S. patent-term extension moved the expiry of RE47,739 to 5 March 2027. FDA records also identify later patents and potential 180-day generic exclusivity.

March 2027 is therefore a significant patent milestone rather than an uncontested product-level LOE date.

From an engineering perspective, palbociclib may require potent-compound controls, including contained dispensing and transfer, local exhaust ventilation, dust extraction, pressure control, equipment containment, campaign manufacturing, cleaning validation and controlled waste handling.

Trintellix — Vortioxetine

Trintellix is an immediate-release oral antidepressant marketed in the United States by Takeda. U.S. Patent 7,144,884 reached its identified expiry date on 17 June 2026, while FDA records continue to reference other patents, litigation and potential shared 180-day exclusivity.

A manufacturing assessment should review API solid-state characteristics, particle-size distribution, blend and content uniformity, dissolution, coating, stability, packaging and analytical-method transfer. Where an existing OSD plant is proposed, available dispensing, compression, coating, packaging and laboratory capacity should also be evaluated.

Rexulti — Brexpiprazole

Rexulti is an oral antipsychotic marketed by Otsuka with Lundbeck. FDA records identify four patents that expired on 12 April 2026, but later patents continue through December 2028 and October 2032.

For the reviewed Apotex ANDA, FDA stated that final approval could not be granted before 23 December 2028 based on the applicant’s certifications unless another legal or regulatory basis supported earlier approval.

Rexulti demonstrates why the expiry of several patents on one date cannot be treated as a complete LOE assessment.

Gilotrif — Afatinib

Gilotrif is an oral oncology medicine marketed by Boehringer Ingelheim. FDA records identify RE43,431 through 13 July 2026, while other patents continue beyond that date. The reviewed application received tentative approval, reinforcing the difference between technical regulatory acceptability and permission for commercial marketing.

A manufacturing programme may require potent API handling, HVAC segregation, differential-pressure control, contained transfer, equipment cleanability, cleaning limits, waste management and strong analytical capability.

Symproic — Naldemedine

Symproic is an oral treatment for opioid-induced constipation. Current U.S. ownership and commercial arrangements are more complex than a simple originator-versus-generic description. FDA records identify BioDelivery Sciences International as the NDA applicant, while Collegium states that it licenses U.S. commercialization rights from Shionogi.

A proposed 5 October 2026 date should not be published as a product-level U.S. LOE date until the current Orange Book patent stack, litigation position and any settlement or licensed-entry arrangements are reconfirmed.

Products Close to, but Outside, FY2026–27

Januvia and Janumet — Sitagliptin Products

For U.S. Januvia tablets, FDA records identify U.S. Patent 7,326,708 through 24 May 2027, after the end of FY2026–27. Immediate-release Janumet records include the same date and another patent through January 2029.

Januvia, Janumet and Janumet XR are separate products and applications and should not be combined into a single expiry date. They may still be relevant to medium-term planning for API sourcing, fixed-dose-combination development, high-volume compression, coating, packaging and analytical capacity.

Uptravi — Selexipag

Johnson & Johnson identifies pediatric exclusivity for U.S. Patent 7,205,302 through 30 April 2027 and lists additional patents extending into 2030, 2031 and 2037. The April 2027 date is outside FY2026–27 and is not the end of all U.S. protection.

Products Removed from the 2026 Opportunity Set

Erleada should not be presented as a March 2027 overall LOE opportunity because Johnson & Johnson identifies 2030 as the U.S. composition-of-matter patent expiry year and lists later patents.

Imbruvica should also be excluded from a straightforward 2026 opportunity list. Johnson & Johnson identifies 2028 as the U.S. composition-of-matter patent expiry year.

Sprycel is not awaiting initial U.S. generic entry; Bristol Myers Squibb reports that generic versions have entered the United States, European Union and Japan.

Saphris is also not a new first-entry opportunity arising from an October 2026 patent date because FDA approved an asenapine sublingual-tablet ANDA in 2018.

What the FY2026–27 Patent Landscape Means for Manufacturers

FY2026–27 Patent Landscape Means for Manufacturers

Patent milestones can support early portfolio screening, but manufacturing decisions should follow legal, regulatory, technical and engineering verification.

Legal and Regulatory Verification

Before committing engineering expenditure, companies should confirm the intended jurisdiction, current patent records, remaining formulation and method-of-use patents, patent-term or pediatric extensions, regulatory exclusivity, ANDA status, Paragraph III or IV certifications, label carve-outs, 180-day exclusivity, litigation, settlements and licensed-entry arrangements.

Engineering teams may use this information to develop schedules, but freedom to operate and commercial-launch risk should be assessed by qualified legal and regulatory advisers.

API, Formulation and Containment Readiness

The technical assessment should confirm that the API and finished product can be developed, scaled and transferred reproducibly. Key questions include route scalability, starting-material availability, impurity control, solid-state properties, particle size, dissolution, bioequivalence, analytical transfer, stability, packaging and cleaning limits.

For oncology or low-dose oral products, containment should be based on product-specific toxicological and occupational-exposure assessments. The resulting strategy may affect dispensing, closed transfer, local exhaust ventilation, dust extraction, room pressures, equipment segregation, campaign planning, cleaning validation and waste handling.

Capacity, Utilities and Technology Transfer

Capacity planning should consider commercial demand, batch size, campaign length, utilisation, changeover time, yield, packaging throughput, laboratory capacity, warehousing, maintenance access and future expansion.

Utility loads should be calculated from the actual equipment sequence and production strategy. Depending on the process, requirements may include purified water, process gases, compressed air, steam, chilled water, HVAC utilities, electrical systems, BMS, EMS and process automation.

Technology transfer must connect formulation and process knowledge with the receiving site’s equipment, utilities, automation, procedures and quality systems. Equipment-gap assessments, engineering batches, analytical transfer, cleaning development, registration batches, process qualification and continued verification should be planned early.

How Pharma Access Supports Patent-Driven Manufacturing Plans

Once a product opportunity has been independently verified, Pharma Access can assess whether it fits within an existing facility or requires a dedicated line, brownfield expansion or greenfield project.

The assessment may cover:

Feasibility and Project Planning

  • Facility feasibility and capacity assessments
  • Production-volume and expansion planning
  • Brownfield and greenfield project evaluation

Pharmaceutical Engineering and Process Design

  • Pharmaceutical facility engineering design
  • Process-flow and production-layout development
  • Personnel and material movement planning
  • GMP-facility integration

Equipment, Cleanrooms and Utility Systems

Procurement, Construction and Installation

Commissioning, Qualification and Validation

  • Commissioning and qualification planning
  • Facility, utility and equipment validation
  • CQV documentation and execution support

Project Management and EPCMV Delivery

  • Integrated project and schedule management
  • Engineering, procurement and construction coordination
  • EPCMV project-delivery support
  • Brownfield expansion and operational-site coordination

Pharma Access can then support engineering design, equipment planning, vendor coordination, construction, installation, Site Acceptance Testing, commissioning, qualification, validation and project management.

For brownfield projects, the strategy may also address phased execution, temporary routes, tie-in planning, HVAC shutdowns, construction controls and protection of adjacent GMP operations.

This integrated approach connects a verified product strategy with realistic capital requirements, engineering deliverables and execution schedules. Pharma Access does not provide patent opinions, predict court decisions or guarantee generic entry. Its role is to develop practical, compliant and scalable manufacturing infrastructure after the legal, regulatory and commercial pathway has been established.

Why Choose Pharma Access?

Preparing for a generic or pharmaceutical manufacturing opportunity requires more than identifying a molecule and patent date. The facility must reflect the process, product characteristics, containment requirements, production volume, target markets and long-term operating strategy.

Pharma Access provides integrated pharmaceutical engineering and turnkey project-delivery support across feasibility, process and equipment planning, cleanrooms, HVAC, utilities, automation, construction, installation, CQV, project management and EPCMV delivery.

Whether the project involves an OSD line, potent oncology facility, API unit, sterile production or biotechnology infrastructure, Pharma Access helps translate manufacturing requirements into an executable engineering and project-delivery plan.

Planning capacity for a new generic, API or pharmaceutical product? Connect with Pharma Access to evaluate process, facility, equipment, containment, utility and CQV requirements before major project decisions are finalised.

The patent and exclusivity information in this article is provided for general industry awareness and is based on publicly available information reviewed as of 14 July 2026. Patent status, litigation, regulatory exclusivity and market-entry timelines may change and vary by jurisdiction, formulation, dosage form, indication and product. Companies should complete independent legal, regulatory and commercial due diligence before making manufacturing or investment decisions.

Source Register

ProductJurisdictionClaim verifiedSource title, organization and dateQualification or uncertainty
Eliquis — apixabanUnited StatesPatents 6,967,208 to 21 Nov 2026 and 9,326,945 to 24 Feb 2031; tentative ANDA conditionsApixaban Tablets, ANDA 209810 Tentative Approval, FDA, 19 Aug 2020 (FDA Access Data)The FDA letter reflects the applicant’s status on that date and does not establish current commercial launch.
Eliquis — apixabanU.S. and EUBMS estimates U.S. minimum market exclusivity in 2028; EU COM patents/SPCs expire Nov 2026Bristol Myers Squibb 2025 Form 10-K, BMS/SEC, filed 2026 (SEC)Company business-planning estimate; EU litigation and entry are country-specific.
Januvia — sitagliptinUnited StatesPatent 7,326,708 with pediatric exclusivity through 24 May 2027Sitagliptin Tablets USP, ANDA 212952 Tentative Approval, FDA, 11 Feb 2025 (FDA Access Data)May 2027 is outside FY2026–27; 180-day exclusivity remains relevant.
Janumet — sitagliptin/metforminUnited StatesPatents through 24 May 2027 and 21 Jan 2029Sitagliptin and Metformin Hydrochloride Tablets, ANDA 212338, FDA, 7 Jan 2025 (FDA Access Data)Applies to the specified immediate-release strengths and application, not automatically to Janumet XR.
Ibrance — palbociclibUnited StatesPTE extended RE47,739 to 5 Mar 2027Pfizer Confirms U.S. Patent Term Extension for Ibrance, Pfizer, 5 Feb 2021 (Pfizer)This is one patent milestone.
Ibrance — palbociclibUnited StatesFDA-listed patents also extend to 2034 and 2036; ANDA approvedPalbociclib Tablets, ANDA 215570 Approval, FDA, 28 Aug 2023 (FDA Access Data)ANDA approval does not by itself resolve patent litigation or establish commercial launch timing.
Erleada — apalutamideUnited StatesCOM patent expiry year 2030; selected secondary patents expire 27 Mar 2027; later patents continueInformation About Our Innovative Medicine Patent Portfolio, Johnson & Johnson Innovative Medicine, updated 10 Feb 2026 (Q4 Inc.)The company table is expressly non-exhaustive and advises checking the current Orange Book.
Imbruvica — ibrutinibUnited StatesCOM patent expiry year 2028; additional Orange Book patents apply across multiple NDAsSame J&J patent portfolio, 10 Feb 2026 (Q4 Inc.)Full product-level patent and litigation analysis remains necessary.
Sprycel — dasatinibU.S., EU and JapanGeneric products have entered all three marketsBristol Myers Squibb 2025 Form 10-K, BMS/SEC, filed 2026 (SEC)Current supplier count, price and market share were not assessed.
Trintellix — vortioxetineUnited StatesPatent 7,144,884 expired 17 Jun 2026; other patents extend through 2032Vortioxetine Tablets, ANDA 211146 Approval, FDA, 17 Sep 2021 (FDA Access Data)FDA documented continuing litigation and potential 180-day exclusivity issues.
Rexulti — brexpiprazoleUnited StatesFour patents expired 12 Apr 2026; later patents to Dec 2028 and Oct 2032Brexpiprazole Tablets, ANDA 213731 Tentative Approval, FDA, 13 Dec 2023 (FDA Access Data)Applies to the reviewed applicant and its certifications; other applicants may have different positions.
Uptravi — selexipagUnited StatesCOM patent with pediatric exclusivity to 30 Apr 2027; later patents to 2037J&J patent portfolio, updated 10 Feb 2026 (Q4 Inc.)April 2027 is outside FY2026–27 and is not the end of all listed protection.
Gilotrif — afatinibUnited StatesRE43,431 to 13 Jul 2026; other patents through 2031; tentative ANDA statusAfatinib Tablets, ANDA 210804 Tentative Approval, FDA, 14 Feb 2023 (FDA Access Data)Current final-approval and launch status should be rechecked immediately before publication.
Symproic — naldemedineUnited StatesCurrent NDA applicant identified as BDSI; Collegium commercializes under Shionogi licenceSymproic NDA 208854/S-007 Supplement Approval, FDA, 15 Jul 2025; Collegium 2025 Form 10-K, filed 2026 (FDA Access Data)Complete current Orange Book patent stack and entry conditions require further verification.
Saphris — asenapineUnited StatesGeneric asenapine ANDA approved in 2018Asenapine Sublingual Tablets, ANDA 206107 Approval, FDA, 17 Jul 2018 (FDA Access Data)Patent records at approval included patents through Oct 2026, demonstrating that approval and patent expiry are separate issues.
Saphris — asenapineUnited StatesCurrent branded NDA applicant identified as AbbVieSaphris NDA 022117/S-24 Supplement Approval, FDA, 22 Jan 2025 (FDA Access Data)Commercial ownership and licensing arrangements can change and should be rechecked before publication.

Frequently Asked Questions

Which pharmaceutical patents are expected to expire in 2026?

Selected U.S. milestones include an Eliquis patent on 21 November, a Trintellix patent on 17 June, four Rexulti patents on 12 April and a Gilotrif patent on 13 July. These are individual patent dates, not confirmed product-level LOE dates.

Does patent expiry allow immediate generic entry?

No. Other patents, regulatory exclusivity, litigation, settlements, tentative approval, 180-day exclusivity or labelling issues may still delay entry. Manufacturing readiness, stability, bioequivalence and cGMP compliance may also affect launch timing.

How early should capacity planning begin?

Planning should begin early enough to complete feasibility, development, equipment selection, procurement, facility work, technology transfer, CQV and regulatory batches before the intended commercial date. The schedule depends on dosage form, containment needs, existing infrastructure and equipment lead times.

Why is CQV important when adding a manufacturing line?

CQV provides documented evidence that facilities, utilities, equipment and systems are installed and operate as intended. Considering CQV during design allows user requirements, design reviews, vendor documentation, FAT, SAT, IQ and OQ activities to be developed as one coordinated programme.

Posted on

How Much Can a Modern Pharma Facility Actually Save on Energy Costs Long-Term?

Modern Pharma Facility Energy Costs

Energy bills at a pharma plant are not like the energy bills at a normal office building. A single cleanroom can use far more power per square foot than a standard commercial space, much of which is used to keep the air clean, cool,within specified humidity limits  and at the right pressure. Once you know where your money is going, it is much easier to see where you can save it. This post takes a look at published industry benchmarks for  modern pharma facility energy costs, the big drains, and what facilities have actually saved after they made changes.

Why Energy Costs Run So High in Pharma Manufacturing

A typical commercial office building constructed after 2000 has been reported to use approximately 81 kBtu per square foot annually. According to a report published by Consulting-Specifying Engineer, some pharmaceutical manufacturing facilities have recorded energy-use intensities of approximately 1,210 kBtu per square foot annually. Much of that difference is associated with one major system: HVAC. Cleanrooms require a continuous flow of filtered air to maintain particle counts within limits, and that air may need to be heated, cooled, humidified, or dehumidified for extended operating periods.

Many critical pharmaceutical environments maintain controlled conditions continuously, even when production is not active. However, validated temperature or airflow setbacks may be possible during non-production periods where they are supported by quality risk assessment, monitoring, qualification and change control.

HVAC is not the only contributor to pharmaceutical-facility energy consumption. Process equipment, sterilisation systems, purified-water generation, clean steam, refrigeration, compressed air and other central utilities may also represent substantial energy loads.

The HVAC Component Driving Energy Costs in Modern Pharmaceutical Facilities

The HVAC Component Driving Energy Costs in Modern Pharmaceutical Facilities

HVAC systems account for a large share of total plant energy use across the industry.

  • According to ISPE, and data referenced in the U.S. EPA ENERGY STAR pharmaceutical-industry guide, HVAC use in cleanrooms has been reported to account for approximately 36% to 67% cleanroom energy consumption, depending on the room class and process.
  • Another ISPE article on cleanroom design points out that many sites have over 50% plant HVAC electricity use over 50%, noting that pharma cleanrooms can use up to 15 times more energy than a typical commercial building.
  • Research by Lawrence Berkeley National Laboratory shows that HVAC systems can comprise as much as two-thirds of the energy used by labs and cleanrooms, as cited in the U.S. EPA’s ENERGY STAR guide for the pharmaceutical industry.

That range  approximately one-third to two-thirds of energy use in many cleanroom environments, depending on the source, system boundary and site is the reason why just about every real energy story in pharma begins with HVAC.
It is important to distinguish between total facility energy, electricity consumption, cleanroom energy and HVAC-system energy. Savings measured in one category should not automatically be interpreted as an equivalent reduction in the facility’s total utility bill. 

How Much Can a Modern Pharma Facility in Energy Actually Save?

How Much Can a Modern Pharma Facility in Energy Actually Save?

Here’s what the numbers look like if you make changes, based on published case data:

The examples below include historical case studies compiled in industry and ENERGY STAR guidance. Their engineering principles remain relevant, but current tariffs, equipment costs and payback periods should be recalculated for each project.

Airflow optimisation. Reducing unnecessary airflow can lower fan, heating and cooling demand. However, any reduction in air-change rates must be supported by process risk, room recovery performance, contamination-control requirements, qualification and environmental monitoring.

  1. HVAC recommissioning: The ENERGY STAR pharmaceutical guide cites a recommissioning project at Pfizer’s Morris Plains, New Jersey site, which reduced its net energy use per degree-day by 21%.
  2. Metering and monitoring upgrades: Wyeth’s Fort Dodge Animal Health plant in Campinas, Brazil installed a metering and control system that cut electricity use by 48% and reduced plant utility costs by 10%.
  3. Merck’s labs in Rahway, N.J., lowered room temperatures during off hours, saving nearly 30,000 MBtu a year across 350,000 square feet of lab space overnight and on weekends.The strategy was applied to selected laboratory areas where reduced temperatures would not affect equipment or scientific operations. 
  4. Dynamic airflow management :Dynamic airflow management can reduce ventilation demand by moving away from continuously operating at fixed, worst-case airflow conditions. Commercial engineering estimates have indicated potential reductions of approximately 20% to 40% in HVAC energy consumption in suitable applications.
    This should not be described as a direct EU GMP Annex 1 requirement. Annex 1 requires a documented Contamination Control Strategy, Quality Risk Management, qualified cleanroom performance and appropriate monitoring. Any dynamic airflow strategy must demonstrate that validated environmental conditions and pressure relationships remain consistently maintained. 
  5. Variable-air-volume (VAV) systems: According to a laboratory case study cited in the U.S. EPA ENERGY STAR guide, a VAV system used 30% to 50% less energy than the older air-control system it replaced.
    This figure should be treated as a project-specific result rather than a guaranteed saving for every pharmaceutical facility. Actual performance depends on minimum validated airflow, occupancy, process loads, room classification, pressure requirements and control sequences. 

None of this involved the replacement of whole buildings. The savings came from modifying how existing systems operated, improving controls and monitoring, or designing the systems correctly from the beginning.

Real Facilities, Real Numbers

Real Facilities, Real Numbers

The examples above are from operating plants, not from laboratory tests. A good one to study closely is Genentech’s site in Vacaville, Calif. The team went with two large chillers and one smaller unit instead of three matched units. This way, the big chillers run close to full load, where they use less power per ton. The ENERGY STAR pharmaceutical guide said the decision was expected to save about $113,250 annually. The same facility also reset its discharge air temperature during low-demand periods, saving nearly $150,000/year in chilled water and steam usage.

These are no one-shot paybacks. Once the system correctly installed, controlled, commissioned and maintained, you will see the savings on every utility bill thereafter, year after year, for the life of the equipment.

However, long-term savings depend on maintaining sensors, control sequences, filters, dampers, valves and equipment performance. Without ongoing monitoring and recommissioning, systems can gradually drift away from their intended operating conditions. 

Biopharmaceutical Facility Design Sets the Ceiling on What’s Possible

Here’s the part that matters most for anyone contemplating a new build: the decisions made in Biopharmaceutical Facility Design dictate most of what’s even possible to save later. An oversized HVAC system, poor zoning, or a one-size-fits-all air change rate will always cost more to operate than a properly sized system, no matter how well it is operated afterwards.

ISO 14644-16 provides guidance for improving energy efficiency in new and existing cleanrooms while maintaining the required environmental performance. It supports evidence-based evaluation of airflow, air-distribution effectiveness, operating modes and energy performance rather than relying only on inherited or overly conservative design assumptions.

Hence, the importance of declassifying a room, right-sizing equipment, and correctly mapping pressure cascades at the design stage. A cleanroom specified at a cleaner classification than the process requires can increase airflow demand, capital cost, qualification effort, monitoring requirements and long-term operating expenditure without providing a corresponding product-quality benefit.

Why Turnkey Pharmaceutical Projects Change the Math

Energy decisions are often made in a vacuum when design, construction, and equipment selection are done under separate contracts. The HVAC engineer sizes it for one set of assumptions, then the process team changes the layout, and the numbers don’t match. Turnkey pharmaceutical projects connect these interdependent decisions through an integrated delivery structure. One team handles the work from the initial design phase all the way through construction and validation. With engineering design, construction, and project management all under one roof, a firm like Pharma Access can follow an HVAC decision made in the design phase through to the equipment installed on site reducing the risk of design intent being weakened during handovers between disciplines, contractors and project stages.

Engineering Design Services for Pharma: Where the Savings Get Locked In

Engineering Design Services for Pharma

Good engineering design services for pharma begin with a hard look at the actual process, not a generic template. It also means matching air change rates to actual contamination risk, zoning HVAC systems by room class rather than running one system for the whole plant, and sizing chillers and pumps to the load the facility will actually see.

Air-change rates should not be selected by room classification alone. They should be developed using process risk, product exposure, occupancy, contamination generation, room recovery, airflow effectiveness, pressure relationships and qualification requirements. 

Pharma Access works in exactly this way on its engineering design projects. This includes HVAC, MEP, and clean room layout together, so the systems are sized to match the process and not a worst-case guess.

Pharma Access coordinates process requirements, cleanroom classification, HVAC zoning, pharmaceutical utilities, equipment selection, automation and CQV considerations during engineering development. This integrated approach helps align system capacity with actual manufacturing requirements rather than isolated assumptions developed by individual disciplines.

Energy-efficiency opportunities may include optimised airflow distribution, correctly sized air-handling and chilled-water systems, lower system pressure drops, efficient motors and drives, heat recovery where technically suitable, building-management-system monitoring and validated operating setbacks. Every measure must remain compatible with GMP, product protection, operator safety and the facility’s Contamination Control Strategy.

A Simple Way to Think About the Payback

This order works well if you’re planning a new build or an upgrade.

  1. Get a baseline. Know your existing energy use per square foot before you start and separate HVAC, process equipment, utilities and other major loads wherever submetering data is available.
  2. Compare air change rates with ISO 14644-16 and identify rooms that are over-ventilated for their real risk level.
  3. Use ISO 14644-16 as cleanroom energy-efficiency guidance, but assess any proposed airflow change through Quality Risk Management, room-performance data, qualification, environmental monitoring and formal change control. 
  4. Consider HVAC recommissioning before buying new equipment.An Ethicon facility in Somerville, New Jersey, implemented a recommissioning project at a reported cost of approximately $53,000. The project generated approximately $48,000 in annual gas and electricity savings, giving a simple payback of around 1.1 years.
  5. Add monitoring and controls to catch drift before it turns into a bigger bill.
  6. Integrate design, construction, and project management into one plan so energy choices last from blueprint to start-up.
  7. Continue monitoring performance after qualification. Energy savings will only remain sustainable when sensors, controls, equipment and operating procedures continue to perform as intended.

FAQs

How much of a pharma plant’s energy bill comes from HVAC? 

Published studies put it somewhere between approximately 36% and 67% of cleanroom energy consumption, depending on room class and process. Sterile and biotech cleanrooms tend to be on the high end generally because they require constant, tightly filtered airflow at all times.

However, the exact percentage varies according to the facility boundary being measured, the manufacturing process, outside-air requirements, climate, operating hours and the contribution of process equipment and pharmaceutical utilities. 

Can an existing pharma facility cut energy costs without a full rebuild? 

Yes. Recommissioning, airflow adjustments, and temperature setbacks during off-hours have achieved reductions of approximately 10% in total utility cost, more than 20% in weather-normalised energy use, and substantially higher reductions in selected electrical or HVAC loads at actual sites, based on ENERGY STAR and ISPE case data.
Payback periods vary by intervention, tariff, operating schedule, system condition and capital requirement. Some low-cost control and recommissioning projects have achieved payback in approximately one to two years, while equipment-intensive upgrades may take longer.

Does a smaller cleanroom cost less to run? 

Generally, a smaller cleanroom requires less total conditioned airflow than a larger room with identical conditions. However, floor area alone does not determine operating cost.

Room class, room volume, ceiling height, airflow rate, outside-air demand, temperature and humidity requirements, pressure cascade, process heat load and operating schedule drive cost.

A small over-classified room can cost significantly more per square metre than a larger room configured with the proper airflow for its actual use.

What’s the difference between hiring separate firms and using turnkey pharmaceutical projects? 

Design and construction decisions that are separately contracted can drift apart over time. A turnkey pharmaceutical project means one team is responsible for the entire process from design to startup. 

That means greater continuity and accountability for energy-related decisions throughout engineering, procurement, construction, commissioning and qualification.

It does not remove the need for design reviews, approvals or change control, but it can reduce interface risks and help preserve agreed performance requirements.

When is the best time to plan for lower energy costs: design or after construction?

Design, it is far cheaper to get air changes, chiller sizing, and HVAC zoning right on paper than to fix them once the building is up and validated. Existing facilities can still achieve meaningful savings through recommissioning, monitoring, controls optimisation and targeted upgrades. However, new projects have the greatest opportunity to influence lifecycle cost before equipment capacities, layouts and system configurations become fixed. 

Posted on

How Are Companies Using AI for Predictive Maintenance in Their New Pharma Plants?

AI for Predictive Maintenance in Pharma Plants

A tablet press breaking down at 2 a.m. doesn’t just mean a repair bill; it also means a loss of production.trigger a product-impact assessment, a deviation investigation, additional testing or a line that remains idle while the engineering and quality teams investigate. That one breakdown is why many pharma companies are now incorporating AI for predictive maintenance into their new facilities, rather than adding it later.

This piece examines what that really looks like on the ground: the sensors, the software, the personnel, and the practical challenges of operating in a GMP-regulated environment, including in a market like Mumbai.

What Predictive Maintenance in Pharma Plants Actually Means

What Predictive Maintenance in Pharma Plants Actually Means

Most older plants still run on a combination of corrective maintenance and scheduled preventive maintenance: fix it when it breaks, or service it on a fixed calendar, whether or not it needs it. Both approaches have limitations when they are used without appropriate condition monitoring. Breakdown maintenance halts the line without warning. Maintenance by calendar often replaces parts that still have life left in them or misses a problem that shows up between two scheduled visits.

Predictive maintenance in modern pharma plants introduces a condition-based approach supported by equipment data and analytics. Vibration, temperature, motor current and pressure sensors can be installed on selected compressors, centrifuges, tablet presses, HVAC components and filling-line equipment to collect data continuously or at defined intervals, depending on the asset and its operating condition. A machine learning model trained on this data can establish expected operating patterns and identify changes associated with defined degradation or failure modes before functional failure occurs.

Briefly:

  • Preventive maintenance is calendar-based.
  • Predictive maintenance is based on the actual condition of the equipment.

The second method can identify selected degradation patterns that scheduled maintenance may not detect between inspections and can reduce unnecessary maintenance interventions. However, it does not replace statutory inspections, calibration activities, safety checks or preventive maintenance tasks that remain necessary under the approved maintenance programme.

Why New Plants Are Designing This In From Day One

You can retrofit sensors and software on old equipment, but it’s slower and more expensive than wiring a new facility for it from the get-go. This is why AI and automation are increasingly being considered as part of the core engineering brief for greenfield pharma projects, not as an add-on.

It’s important to recognise that predictive maintenance is just one part of a broader transition toward pharma manufacturing automation in new facilities. Several factors are driving this trend.

The costs of sensors, edge devices and data platforms have decreased for many applications, making broader equipment monitoring more feasible. However, monitoring should still be based on asset criticality, identifiable failure modes and a clear business or quality-risk justification rather than automatically covering every asset in the plant.

Regulatory agencies are giving increasing attention to the controlled use of AI within the pharmaceutical product lifecycle. The US FDA’s January 2025 draft guidance presents a risk-based framework for assessing the credibility of AI model outputs used to support regulatory decision-making concerning drug safety, effectiveness or quality, including relevant manufacturing applications. It does not specifically mandate predictive maintenance, but it reinforces the need for defined context of use, appropriate data, model governance and human oversight when AI outputs influence regulated decisions.

Export-oriented manufacturers and pharmaceutical clients may also place greater value on accessible and traceable electronic equipment-health and maintenance records. However, properly controlled paper records can remain acceptable, and the use of an electronic system does not by itself establish GMP compliance.

Losing a batch on a new, costly line is significantly more expensive than losses on depreciated equipment.

How AI for Predictive Maintenance in Pharma Plants Works, Step by Step

How AI for Predictive Maintenance in Pharma Plants Works, Step by Step

Here’s a quick breakdown of the daily run of this on a modern line:

  1. Sensors gather data: Vibration, temperature, torque, and pressure readings are taken from equipment such as tablet presses, granulators, autoclaves, and lyophilisers at a sampling frequency engineered for the equipment, its operating cycle and the degradation mechanism being monitored.
  2. Data goes to a central platform: Readings are ingested into a cloud or on-premise system along with data from the plant historian, MES, and existing SCADA systems. Depending on the application, information may also be integrated from the BMS, EMS, CMMS or enterprise asset-management system. Cloud deployment requires appropriate consideration of cybersecurity, access control, data ownership, availability and backup arrangements. 
  3. Machine learning algorithms search for drift: Models compare live readings with known equipment behaviour and known failure patterns such as bearing wear signatures or seal degradation.
  4. The system raises an alarm before a breakdown: Maintenance receives an early indication when the monitored condition exceeds an approved threshold or the model detects an abnormal operating pattern. The available warning period can range from a short interval to several weeks or months, depending on the failure mode, equipment condition, operating profile and quality of the available data.
  5. Work orders and records are automatically created: Where the analytics platform is appropriately integrated with a CMMS or enterprise asset-management system, reviewed alerts can initiate an approved assessment or work-order process. The configuration, approval route and associated electronic records should be governed according to the system’s GxP impact and the organisation’s maintenance and quality procedures. 

That’s the flow that makes a featured snippet-worthy answer to “How does predictive maintenance work in pharma?”: sensors collect, software analyses, the system alerts early, and the team acts on a schedule, not a surprise.

The Real Benefits Companies Are Reporting

The Real Benefits Companies Are Reporting
  • Fewer unplanned stopovers: Identify equipment drift early, and you’ll lose fewer batches to a mid-run breakdown.
  • Prolonged equipment life: By basing service on actual wear and tear, rather than on a fixed calendar, unnecessary replacement of parts and stress on machinery are reduced.
  • Stronger compliance posture: An unplanned failure of a reactor, centrifuge or critical utility component is not simply a downtime event. It may result in a deviation investigation, product-impact assessment, further testing and, in some cases, batch rejection. Detecting a developing condition early may reduce the probability of a product-impacting failure and provide more information for a timely engineering and quality assessment. It does not automatically eliminate the need for deviations, change control or other quality-system actions.
  • Reduced cost of ownership: Fewer emergency repairs, fewer rush orders for spare parts, fewer overtime hours for maintenance workers.

Pharma Engineering Solutions with AI: Where This Fits in Plant Design

Often, the best results are from projects where automation and monitoring are part of the engineering design process with AI and not added after commissioning. This means deciding at the design stage where sensors are placed, how data flows between the process control layer and the maintenance software, and how the whole setup lines up with commissioning, qualification, and validation (CQV).

This is where companies offering integrated pharmaceutical engineering, automation and digital-infrastructure solutions can bring real value. Pharma Access, for example, works at this very intersection for its turnkey pharma projects, coordinating HVAC, pharmaceutical utilities, process systems, automation, BMS, EMS, IT/OT infrastructure and CQV requirements so that a new facility can be designed with the infrastructure needed to support condition monitoring and future analytics applications. Getting this sequence right at the design stage avoids costly rework once the plant is running.

Challenges in Pharmaceutical Companies in Mumbai and Across India

Mumbai and the broader Indian pharma belt have real strengths here: a large pool of engineering talent, strong export volumes, and companies that already compete on the global stage. However, the challenges faced by pharmaceutical companies in Mumbai and other manufacturing hubs are not small.

Common barriers include:

  • Site-specific infrastructure readiness: Power quality, network reliability, server architecture and cybersecurity capabilities vary between facilities and locations. New projects should therefore assess redundancy, backup power, offline data buffering and system-recovery requirements during the engineering stage.
  • The transition between paper-based and electronic records: Regulatory and inspection environments may involve paper-based, electronic or hybrid documentation. Companies implementing AI-enabled condition monitoring should ensure that relevant records remain controlled, accessible, traceable and suitable for review regardless of the inspection format.
  • Talent and change management: Maintenance teams require training to understand, evaluate and act on AI-generated alerts rather than viewing the system as just another dashboard. Engineering judgement remains essential because an alert should support, rather than replace, a qualified person’s assessment.
  • Budget pressure: Small and mid-sized manufacturers may see digital monitoring platforms as an IT cost rather than an investment in plant reliability, making them slower to adopt than larger export-oriented firms. A phased implementation focused on critical assets can provide a more practical route than attempting plant-wide deployment from the beginning.

The opportunity is that greenfield projects in India can incorporate scalable digital and automation infrastructure from the design stage, avoiding some of the integration constraints that arise when condition-monitoring systems are retrofitted into legacy facilities.

What Regulators Expect

Globally, the FDA has released a draft guidance from January 2025 that explains a risk-based approach to establishing the credibility of AI model outputs used to support regulatory decision-making regarding the safety, effectiveness or quality of drugs and biological products. The guidance can be relevant to manufacturing applications when an AI output supports a regulated quality or regulatory decision, but it is not a predictive-maintenance standard and does not require manufacturers to implement AI-based maintenance.In India, the CDSCO continues to move forward with digital initiatives, including its Digital Drugs Regulatory System. At the same time, pharmaceutical manufacturers should be prepared to present reliable and understandable maintenance information during inspections conducted through paper-based, electronic or hybrid workflows. 

Pharma manufacturers who are deploying automation and condition monitoring need systems that provide clear, timestamped, audit-ready records, not just alerts on a screen, so that domestic and international inspectors can trace every maintenance action back to its cause.

Getting the Engineering Right From the Start

Getting the Engineering Right From the Start

The plants with the best results are not those that tacked AI on as an afterthought. They are the ones where the engineering design, the automation layer, and the maintenance strategy were designed together from the first drawing. That is the true difference between a facility that reacts to breakdowns and one that anticipates them.

If you are planning a new facility and want to build in automation and monitoring instead of adding it on later, Pharma Access partners with pharma companies on this exact type of turnkey planning, from engineering design through construction, CQV, and project management.

By considering equipment criticality, sensor infrastructure, automation architecture, data flow, maintenance-system integration and GxP requirements during the design stage, project teams can create facilities that are better prepared for condition-based maintenance and future AI applications. 

Frequently Asked Questions

Is AI predictive maintenance mandatory for new pharma plants in India? 

No, it is not mandatory under CDSCO or Schedule M now. The applicable requirements focus on appropriate equipment maintenance, calibration, documentation and pharmaceutical quality-system controls rather than prescribing AI as a specific technology. Companies may adopt predictive maintenance where it provides a justified reliability, quality-risk or operational benefit.

How much does predictive maintenance reduce downtime in a pharma plant? 

Results vary from plant to plant, but companies that use real-time analytics and AI monitoring often see significant reductions in unplanned downtime and batch failures, largely because of the ability to detect problems weeks before they become a breakdown.The result depends on asset criticality, detectable failure modes, sensor quality, data history, model performance, maintenance response time and the way the system is integrated into operational procedures. 

What equipment benefits most from predictive maintenance in pharma plants? 

High-value, high-risk assets have the quickest payback. That includes tablet presses, centrifuges, compressors, HVAC, and autoclaves, as a failure on any of those can directly affect the quality of a batch or the classification of the facility.

Does predictive maintenance replace the maintenance team? 

No. It shifts the focus of the team. Now, engineers spend more time doing planned interventions based on real data from the equipment itself rather than routine checks and emergency repairs.The maintenance team still has to assess alerts, determine whether the detected pattern is technically meaningful, coordinate the intervention, complete post-maintenance checks and document the equipment’s return to service. AI supports engineering decisions; it does not replace qualified maintenance personnel. 

Can predictive maintenance help during CDSCO or FDA inspections? 

It can support inspection readiness, but the technology itself does not establish compliance. A well-designed system generates a historical record with time stamps of the condition of equipment and all maintenance activities, which is the audit trail inspectors require during GMP inspections.

Posted on

Top 8 AI Solutions for Pharma Companies in 2026

Top 8 AI Solutions for Pharma Companies in 2026

The question is no longer “should AI be in pharma?” Today, pharmaceutical companies want to know how quickly they can implement AI and realize measurable value from it. AI is changing how pharma companies design, make, and deliver medicines, from the design of a facility to the discovery of a drug.

The shift is quantifiable. By 2026, the pharmaceutical industry will be spending $3 billion on AI, and analysts predict that innovations powered by AI could create $350 billion to $410 billion in annual value for the industry. That includes drug development, manufacturing, clinical trials, and commercial operations.

Here is a breakdown of the top AI solutions that have the most impact on pharma companies today.

1. Pharma Engineering Solutions with AI: Simulation-Based Facility Design

Today, AI allows engineering teams to run the entire facility virtually before construction begins.

Using simulation-based engineering, AI models can test cleanroom airflow, pressure differentials, equipment layouts, and contamination control logic in a digital environment. Problems that usually come up during construction or, worse, during a regulatory inspection, can be identified and resolved  at the design stage.

This is exactly what Pharma Access does. Pharma Access is headquartered in Andheri West, Mumbai. The company creates pharma engineering solutions with AI-assisted simulation at the heart of each turnkey pharmaceutical project. Before the construction period, their engineering team employed sophisticated simulation tools to model HVAC performance, room classification, and material flow paths. The concept is to incorporate GMP compliance into the design rather than attempting to retrofit compliance later in the project lifecycle.

Pharma Access brings this approach to biotech, sterile manufacturing, OSD, oral liquid dosage, and API facility categories with 25+ years of experience and 120+ projects in 18 countries.

2. Digital Twins for Real-Time Manufacturing Monitoring

Digital Twins for Real-Time Manufacturing Monitoring

A digital twin is a real-time data-driven virtual representation of a physical manufacturing system. Feed it sensor data from your production line, and it provides real-time visibility into manufacturing performance and facility operations.

Industry estimates suggest the pharmaceutical manufacturing digital twins market is poised to expand from around $1.3 billion in 2025 to $8.5 billion by 2032, at a CAGR of approximately 30%. That growth reflects the increasing adoption of digital twin technologies across pharmaceutical manufacturing operations.

At the ARC Forum in February 2026, AstraZeneca’s process digital twins were on display, demonstrating how physics-informed models of manufacturing processes can slash material use by up to 25 kg per trial run during development, substituting virtual experiments for physical ones. In 2025, the University of Cambridge and A*STAR collaborated to develop an AI digital twin platform for production lines that automates fault detection, anomaly identification, and predictive maintenance.

Regulatory agencies are increasingly evaluating and supporting model-based approaches through risk-based validation frameworks and data-driven manufacturing initiatives.

3. Predictive Maintenance Powered by IoT and Machine Learning

Predictive Maintenance Powered by IoT and Machine Learning

In a pharmaceutical plant, equipment failure doesn’t just generate a maintenance work order. This leads to batch rejection, a GMP deviation report, and perhaps a regulatory investigation.

Predictive maintenance changes the equation. AI-based systems ingest data from IoT sensors that monitor vibration, temperature, pressure, and flow rates on critical equipment. Machine learning algorithms identify patterns that predict failure and can warn of them days or weeks before a breakdown occurs.

The results are well documented. At a pharmaceutical manufacturer, the implementation of People10’s AI-driven predictive maintenance resulted in reducing unplanned downtime by 25-30%. Across manufacturing sectors, predictive maintenance programs report reductions in downtime of 30–50% and reductions in maintenance costs of up to 40%.

Each maintenance action must be traceable in a GMP environment. Compliant AI maintenance platforms come with audit-ready records compliant with 21 CFR Part 11, including electronic signatures and timestamped logs at each step.

The global predictive maintenance market was valued at $12.7 billion in 2024 and is projected to reach $80.6 billion by 2033, registering a CAGR of 22.8% from 2024 to 2033.

4. AI in Construction and Installation Planning for Pharma Facilities

Pharma construction and installation services have traditionally relied on sequential planning, where one team completes before the next team starts. That’s changing with AI-based project management tools.

AI models now analyze construction sequencing, identify scheduling conflicts before they occur, and highlight dependencies between engineering disciplines. This reduces rework on a typical pharmaceutical facility build, manages vendor coordination across MEP, HVAC, civil, and utility teams, and keeps the project on its GMP qualification timeline.

These tools are being used by pharma engineering consultants in Mumbai and other major pharmaceutical manufacturing hubs to manage the complexities of multi-disciplinary pharma construction projects. An end-to-end pharmaceutical project encompassing engineering design, procurement, construction, and CQV has dozens of parallel workstreams. AI-powered coordination tools consolidate all of them into one manageable view.

5. Automated Regulatory Compliance and Documentation Management

CAPA workflows, regulatory submissions, SOP updates, and audit readiness documentation all take a lot of time in any pharma operation. AI tools designed for compliance management automate the monitoring and updating of these documents.

Compliance AI systems can identify regulatory submission gaps before filing, track CAPA progress, and manage SOP version control across large organizations. The FDA’s 2025 draft guidance on AI models in manufacturing introduces a risk-based credibility assessment framework that requires companies to validate AI outputs using independent test data and documented acceptance criteria.

Automation of compliance workflows reduces human error in sterile manufacturing environments where the risks of contamination are high and the documentation requirements are most stringent, while maintaining full traceability required by regulators.

6. AI-Driven Facility Layout and Material Flow Optimization

AI-Driven Facility Layout and Material Flow Optimization

Facility layout decisions have a direct impact on operational efficiency, GMP compliance, and future scalability. AI-powered simulation tools are helping pharmaceutical companies optimize facility layouts before construction begins.

By analyzing personnel movement, material flow paths, equipment locations, and process interactions, AI models can identify bottlenecks, cross-contamination risks, and inefficient workflows during the design phase. Multiple layout scenarios can be evaluated rapidly to determine the most efficient configuration for manufacturing operations.

These technologies help engineering teams improve space utilization, reduce unnecessary movement, strengthen segregation strategies, and support regulatory compliance. For greenfield facilities and major expansions, AI-assisted layout optimization enables companies to make informed design decisions that improve operational performance throughout the facility lifecycle.

7. Supply Chain Intelligence and Demand Forecasting

Active drug shortages in the U.S. increased by 30% between 2021 and 2022, resulting in a five-year record high of 295 active shortages. In 2019, the FDA found that quality problems caused 62% of drug shortages.

AI supply chain tools help to ward off shortages through demand forecasting, real-time inventory tracking, and supplier risk modeling. They raise the flag on components at risk before they become critical. They model the impact of geopolitical disruption on the availability of raw materials and recommend sourcing alternatives in a proactive way.

Organizations that have implemented AI-enabled supply chain visibility have reported quicker responses to disruption and reduced inventory carrying costs, without compromising product availability.

8. Quality by Design (QbD) Optimisation with Machine Learning

Quality by Design (QbD) Optimisation with Machine Learning

Quality by design is the FDA and ICH-supported approach to building quality in pharmaceutical products by understanding process parameters and their effect on product attributes. QbD is practical for scale with AI.

Machine learning models use historical batch data to identify the process parameters that have the most impact on product quality. This reduces the number of physical experiments required during development, reduces API consumption during trials, and results in more robust manufacturing processes that maintain the specification over production variability.

ICH Q13 provides guidance on continuous manufacturing, where QbD principles and AI-driven process control are closely intertwined.Pharma companies that are now adopting AI-assisted QbD are building the manufacturing knowledge base that will support regulatory submissions under these new guidelines.

How Automation Helps Pharma Manufacturers Stay Ahead

Automation enables pharma manufacturers to minimize manual intervention, enhance batch consistency, and maintain compliance documentation without imposing additional burden on quality teams. 

Key benefits include:

  • Less human error in documentation, inspection, and process control
  • Monitoring in real-time rather than end-of-line testing for quicker detection of deviations
  • Increased regulatory readiness with automated, audit trail-ready documentation
  • Lower cost per compliant batch as predictive tools reduce failures before they occur
  • Shorter product development cycles as simulation replaces physical testing

Regulatory agencies including the FDA, EMA, and WHO continue to emphasize the need for explainable, validated, and traceable AI systems in regulated manufacturing environments. The companies that adopt these tools now will be better positioned when those frameworks become mandatory requirements.

What to Look for in a Pharma Engineering Partner with AI Capabilities

Not every engineering firm provides AI-assisted design and construction. This is what you want to look for:

  • Performance of testing facilities before construction using design tools based on simulation
  • GMP knowledge is built into the engineering team, not added later by external consultants
  • Integrated project management for engineering, procurement, construction, and CQV
  • Experience with dosage forms—Biotech, Sterile, OSD, API, and Oral Liquids all have different engineering needs
  • History of regulatory approvals in multiple countries and agencies

Pharma Access is one of the leading pharma engineering designs, and they bring all five to any project they undertake. The ‘Engicution’ model combines the precision of engineering design with the capability of execution. This approach combines advanced engineering, simulation technologies, and Quality by Design (QbD) principles throughout the facility development lifecycle. They have 70 engineers, 12 subject matter experts, and 8 technical project managers who work on greenfield builds, brownfield expansions, and facility upgrades.

Frequently Asked Questions

1. What are pharma engineering solutions with AI, and why do they matter in 2026?

Pharma engineering solutions using AI apply simulation, machine learning, and digital modeling to allow better design, construction, and monitoring of pharmaceutical plants. They reduce design errors, reduce the cost of GMP remediation, and improve regulatory readiness before construction is complete. They are becoming increasingly important as regulatory expectations continue to evolve and pharmaceutical facilities pursue higher levels of operational efficiency and compliance.

2. How does automation help pharma manufacturers specifically?

Automation allows pharma manufacturers to spot equipment failures before they cause batch losses, minimize manual documentation errors, facilitate real-time environmental monitoring in classified areas, and generate traceable records that meet FDA and EU GMP inspections. The result is better batch consistency, lower deviation rates, and fewer recalls.

3. What is a turnkey pharmaceutical project, and what does AI add to it?

Turnkey pharmaceutical projects offer a fully integrated manufacturing facility, from engineering design through procurement, construction, installation, and validation. AI offers simulation-based design testing, AI-assisted project scheduling, and digital twin capabilities that boost the accuracy of all steps from cleanroom modeling to construction sequencing.

4. What should I look for in pharma engineering consultants in Mumbai for AI-enabled projects?

Look for companies that have validated simulation tools, an engineering team trained in GMP, integrated procurement and construction capabilities, and project experience in the dosage form you are targeting. Just as important as technical capability is regulatory experience in the markets where the facility will operate. Ask them specifically what their design verification approach is pre-construction.

5. How do pharma construction and installation services use AI to stay GMP-compliant?

AI-powered project management tools track construction sequencing, identify clashes between MEP, HVAC, structural, and utility disciplines, and maintain documentation trails that flow directly into commissioning and qualification activities. This means less rework on site and qualification evidence built into the construction record from day one.

Posted on

How Modular Clean Rooms Support GMP Compliance in Pharmaceutical Manufacturing

How Modular Clean Rooms Support GMP Compliance in Pharmaceutical Manufacturing

All drug products reaching patients are based on Good Manufacturing Practice (GMP). Getting it right inside a pharmaceutical facility means controlling the air, the water, the surfaces, and every utility that touches your process. One of the most effective methods manufacturers are using today to meet these needs is modular clean rooms for pharmacy and biotech production.

Let’s examine how modular cleanrooms support GMP compliance in pharmaceutical manufacturing.

What Are Modular Clean Rooms for Pharmacy?

A modular pharmacy cleanroom is a pre-fabricated and pre-engineered controlled environment made from factory-manufactured panels, frames, HVAC modules, and accessories that are assembled on site. Unlike traditional stick-built construction, which assembles raw building materials piece by piece to create clean spaces, modular systems are delivered as finished components ready to install.

The cleanliness of air in the cleanroom is classified by the International Organization for Standardization according to ISO 14644-1:2015. The standard specifies nine classes of air cleanliness according to the maximum allowed number of airborne particles per cubic meter of air. The most relevant classes to pharmaceutical manufacturing are ISO 5, 7, and 8, which are commonly used alongside EU GMP Annex 1 Grades A through D depending on the process and contamination control requirements. For example, ISO Class 5 allows no more than 3,520 particles (≥0.5 µm) per cubic meter — about 100,000 times cleaner than normal room air.

Modular systems can be designed to meet ISO Class 3 through Class 8, with the most common for pharmaceutical applications being Class 5 through 7.

References:

Why GMP Compliance Starts With the Room Itself

Current Good Manufacturing Practice (CGMP) requirements for the manufacture of pharmaceuticals are codified by the U.S. FDA in 21 CFR Parts 210 and 211. Section 211.42 states that buildings shall be of suitable size, construction, and location to facilitate cleaning, maintenance, proper operations, and contamination prevention. The requirements are mirrored in the EU GMP Annex 1, updated in 2022, and are directly mapped to ISO cleanroom classifications.

Here’s why that matters in terms of room design: Regulatory inspectors frequently focus on environmental control deficiencies during inspections, which can result in FDA Form 483 observations, warning letters, and production interruptions. Getting your clean room architecture right from day one is not optional; it plays a critical role in whether your facility can successfully withstand a regulatory audit.

This is where modular pharmacy clean rooms come into play, providing manufacturers with a design that is built and tested to specification before it ever reaches the job site. Panel flatness, joint sealing, surface finish, and HVAC integration have all been confirmed as part of the factory quality control process before installation.

Clean Utilities vs. Black Utilities: Why Both Matter in a Modular Setup

Clean Utilities vs. Black Utilities:

One of the key considerations in pharmaceutical facility design is the distinction between clean and black utilities. This separation, inside a modular clean room, supports GMP compliance and contamination control objectives rather than being solely a design preference.

Clean utilities are utility systems that come into direct contact with the product or the product-contact environment. These include purified water (PW), water for injection (WFI), clean steam, process gases, and compressed air. “Each of these must meet rigid purity specifications, be qualified by qualification protocols, and be continuously monitored throughout the product life cycle.”

Black utilities are infrastructure systems that do not come into direct contact with the product but support facility operations. These include potable water, steam from a standard boiler, chillers, HVAC supply, electrical feeds, fire suppression, and more. Although the black utilities are outside the direct GMP boundary, their reliability has a direct impact on the performance of the clean side. A bad chiller disrupts HVAC temperature control; a boiler outage disrupts sterilization.

In a modular pharmacy clean room system, the clean and black utility zones are physically separated as part of the architecture, from the ground up. The modular wall system pre-designs the routing of WFI loops, clean steam lines, and process gas distribution, eliminating the dead legs and contamination risk points that often occur when improvising utility runs on site with traditional construction.

Modular Cleanroom Accessories That Support Regulatory Performance

Modular Cleanroom Accessories That Support Regulatory Performance

Modular cleanroom panels and frames are just the tip of the iceberg. The accessories that fit into the system have a direct impact on ISO classification and GMP compliance. Here’s what a well-specified modular arrangement typically includes:

  • HEPA and ULPA filtration units are built flush into ceiling grids, providing the necessary airflow and air change rates required to maintain room classification based on the facility’s contamination control strategy and HVAC design requirements.
  • Flush-mounted cleanroom lighting eliminates particle-trapping ledges and meets photometric requirements for production and inspection tasks.
  • Pressure differential pass-through chambers and airlocks between clean zones and adjacent spaces to prevent cross-contamination.
  • GMP-rated doors and windows with smooth, non-porous surfaces and gasket seals to keep classification boundaries at entry points.
  • Cove flooring transitions eliminate the 90-degree angles where particles and microbes can collect.
  • Wall panels with pre-installed environmental monitoring ports for particle counters, temperature probes, and pressure sensors without breaking the cleanroom envelope.

Panel surfaces in GMP-compliant designs should be smooth, non-porous, easy to clean, and resistant to cleaning and disinfection agents. Many manufacturers provide low-surface-roughness finishes to support cleanability and contamination control objectives. The modular panel manufacturers specify these values at the factory level, eliminating the ambiguity of site-applied coatings on traditionally built walls.

The Construction Advantage: Speed, Quality, and Less Risk

The Construction Advantage: Speed, Quality, and Less Risk

The speed of installation is one of the most practical reasons pharmaceutical manufacturers prefer modular pharmacy clean rooms over traditional construction. Studies show that modular systems can be significantly faster to deploy than traditional stick-built equivalents, depending on project scope and site conditions. Typical installation periods for modular cleanrooms can range from several weeks to a few months, whereas traditional construction projects often require substantially longer schedules.

Next steps from a project perspective also become clearer. Off-site fabrication in a factory reduces on-site labor hours—a lean manufacturing case study showed a 41% reduction in field hours for a modular facility with more than 85% of project hours completed off-site.

This is important for GMP compliance, as construction activity can introduce contamination risks that require additional controls and monitoring. In a pharmaceutical facility that’s active every day, a traditional cleanroom build is performed, which creates dust, particles, and moisture that need stringent controls. A modular approach significantly reduces that on-site exposure window.

Compliance also has another underrated benefit: reconfigurability. As regulations change or product lines shift, cleanroom modular panels can be moved, expanded, or upgraded without tearing down the entire space. This protects the long-term capital investment and can simplify future modifications and requalification activities when facility requirements or regulatory expectations evolve.

Pharmaceutical Procurement Consulting: Why Expertise Matters

Specifying and procuring a modular clean room system for a pharmaceutical facility is fundamentally different from purchasing conventional construction materials. The specifications are for structural panel performance, HVAC capacity calculations, filter grades, utility interface requirements, surface material certifications, fire ratings, and documentation packages for commissioning, qualification, and validation.

This is where consulting on pharmaceutical procurement can be a real differentiator. The right consulting partner bridges the gap between design intent and qualified vendors, verifies vendor documentation against applicable GMP and industry requirements, and manages the documentation trail that inspection teams will review. In procurement on a cleanroom project, getting it wrong means spending too much on specifications you didn’t need or underspecifying in areas that will lead to observations during a regulatory audit.

Organizations often benefit from working with experienced engineering and project delivery partners that can integrate design, procurement, construction, installation, and CQV activities under one coordinated approach. Pharma Access provides these capabilities through its turnkey project delivery model. Pharma Access’s team has 25+ years of experience on 120+ pharmaceutical projects in 18+ countries, managing everything from modular clean room design and engineering to procurement, construction, installation, and CQV (commissioning, qualification, and validation). The modular cleanroom design capability is one of a wider turnkey offering that encompasses HVAC system design, piping and plumbing, clean utility routing, and environmental monitoring integration.

Pharma Access also offers project management for facilities planning, sterile manufacturing, OSD, biotech, or API production that keeps regulatory timelines, construction progress, and quality milestones in sync from start to commissioning.

Commissioning, Qualification, and Validation in a Modular Clean Room

Commissioning, Qualification, and Validation in a Modular Clean Room

A modular clean room that meets the criteria of ISO classification is not necessarily GMP compliant. The qualification process includes Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) to demonstrate that the facility and its systems consistently perform as intended.

ISO 14644-2 recommends retesting of ISO Class 5 spaces at a maximum of 6 monthly intervals and ISO Classes 6 through 9 spaces at 12 monthly intervals. In addition to classification testing, GMP requires integrated environmental monitoring of particulates, temperature, humidity, differential pressure, and microbial load mapped against defined alert and action limits.

Manufacturers can benefit from working with experienced teams such as those at Pharma Access, whose CQV services include qualification of both clean and black utilities, to provide a structured path from completion of construction to the first validated batch. Their CQV-centric design methodology is engineered in, not added on at the tail end, closing the gap between design intent and qualified reality.

Frequently Asked Questions

1. What is a modular clean room for pharmacies, and how does it differ from a traditional clean room?

The modular cleanroom for a pharmacy is made up of wall panels, a ceiling system, and integrated HVAC components that are factory-produced and installed on-site. Traditional clean rooms are constructed on-site from raw materials. Modular systems offer faster installation times (typically 4 to 12 weeks versus 6 to 18 months), better quality control during fabrication, and are more easily reconfigured over time as regulatory requirements or product lines change.

2. Which ISO classification do pharmaceutical modular clean rooms typically need to meet?

Most pharmaceutical manufacturing applications are ISO Class 5 through 8 or EU GMP Annex 1 Grades A through D. Aseptic filling and other critical sterile operations require ISO Class 5 (Grade A). The non-sterile formulation and support areas usually run at ISO Class 7 or 8. The precise classification depends on the dosage form, type of process, and applicable regulatory guidelines.

3. What is the difference between clean utilities and black utilities in a pharmaceutical facility?

Clean utilities include purified water, water for injection, clean steam, and process gases. They are in direct contact with the product or the environment in which the product is prepared and must comply with GMP purity specifications and be fully validated with documentation. Black utilities include steam boilers, chillers, potable water, and the HVAC supply air that supports the facility but does not contact the product. While clean utilities generally carry stricter regulatory and qualification requirements, both clean and support utilities must operate reliably to maintain GMP compliance.

4. How do modular cleanroom accessories contribute to GMP compliance?

Accessories such as flush-mounted HEPA filters, pre-installed environmental monitoring ports, pressure-rated pass-through chambers, and GMP-rated doors all contribute to maintaining the classification boundary and contamination controls as specified by ISO 14644-1 and EU GMP Annex 1. The panel surface roughness, coved flooring transitions, and airtight joint systems also directly reduce particle accumulation and microbial risk, all of which are factors that inspectors are trained on in site audits.

5. When should a pharmaceutical company engage a pharmaceutical procurement consultant for a clean room project?

Preferably at the beginning of the engineering design phase. Procurement consulting converts facility design requirements into vendor specifications, checks vendor compliance documentation with current GMP and ISO standards, and manages the documentation package necessary for qualification. The longer you wait to get involved, the more likely you will have specification gaps, rework, or qualification delays that push out product launch timelines significantly.

Posted on

How Poor Infrastructure Impacts Pharmaceutical Product Quality

How Poor Infrastructure Impacts Pharmaceutical Product Quality

A tablet that will not disintegrate. An injectable vial that contains visible particles. Numerous sterile products have been recalled due to microbial contamination. These are not merely regulatory nightmares. They are failures in patient safety, often with one root cause: poor facility infrastructure.

The relationship between a facility’s walls, air systems, and water systems and the medicines manufactured within it is direct and well documented. If the physical environment of a manufacturing plant is compromised, the product contained within is at risk. Let’s take it in pieces.

Why Pharmaceutical Facility Design Is Not Optional

Why Pharmaceutical Facility Design Is Not Optional

Many people think that drug quality is mainly controlled by testing. Run enough checks and catch enough failures, and you keep the bad product off the shelves. That logic sounds reasonable. It actually falls apart.

The design of the manufacturing facility is a core manufacturing control, not an afterthought, as it is treated in the U.S. Food and Drug Administration’s Current Good Manufacturing Practice (cGMP) regulations, 21 CFR Part 211. Design and construction features are required by Section 211.42. Observations related to facility design and construction requirements under 21 CFR 211.42 are consistently among the most frequently cited issues in FDA inspections.

Here’s why that matters: When FDA investigators see conditions that may violate the Food, Drug, and Cosmetic Act, they issue a Form 483. For instance, the FDA issued 561 Form 483s in the drugs sector alone in fiscal year 2024. Deficiencies in facility design and construction and failures in contamination control were among the most commonly cited issues for sterile drug manufacturers in the analysis of these inspections.

The FDA’s own State of Pharmaceutical Quality Report for FY2024 documented 11 product recalls from a single manufacturing site, traced to microbial contamination in stagnant water in a facility duct. Not a process failure. Failure of the facility infrastructure.

What bad facility design looks like in reality:

  • Insufficient differences in air pressure between rooms, with contaminated air moving into clean areas
  • Cross-contamination risks from poorly designed material and personnel flow paths
  • Poor quality surface materials that cannot withstand repeated cleaning and disinfection
  • Insufficient separation in manufacturing grades
  • Aging/non-validated utility systems providing water, compressed air, and steam to production lines

The HVAC Problem: When Air Becomes a Liability

The HVAC Problem: When Air Becomes a Liability

HVAC (Heating, Ventilation, and Air Conditioning) is the highest-stakes infrastructure system in the pharmaceutical plant. If it is right, it is invisible. Get it wrong, and you risk contamination events, batch failures, and regulatory action.

Here’s why. HVAC in a pharmaceutical cleanroom is not a comfort system. It is a validated manufacturing control. HVAC systems are recognized as direct impact systems under 21 CFR Part 211 and EU GMP Annex 1 and require Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). Every pressure differential, every air change rate, and every HEPA filter integrity reading is a GMP parameter.

Recent analyses of GMP inspection findings indicate that a significant proportion of observations in sterile manufacturing facilities relate to HVAC and environmental control deficiencies. Key issues include pressure cascade instability, HEPA filter leakage, and monitoring calibration gaps.

The consequences of getting this wrong are not abstract. A single contamination event due to an HVAC failure in pharmaceutical manufacturing can cost between $2 million and $8 million, when you include the loss of product, the regulatory response, the revalidation, and the investigation costs.

The WHO GMP Annex 8 Guidance on HVAC Systems for Pharmaceutical Facilities requires the use of risk management principles throughout the design, operation, and monitoring. The WHO document calls for specific analysis of failure modes of critical HVAC components, including the impact of fan failure and partial system shutdown. These are not recommendations. These are basic expectations for any facility that supplies medicines anywhere in the world.

Common consequences of HVAC failures include: 

  • Microbial contamination resulting from pressure cascade failures
  • Particulate contamination in sterile production-classified cleanrooms
  • Batch investigations triggered by failed environmental monitoring results
  • Regulatory observations related to 21 CFR 211.42 and 211.113 requirements
  • Production shutdowns and subsequent requalification activities

Water Systems: The Silent Contamination Risk

Water Systems: The Silent Contamination Risk

Water for pharmaceutical use (PW) and water for injection (WFI) are among the most used raw materials in the pharmaceutical industry. They are also, when the systems delivering them are poorly designed or maintained, among the most contamination-prone.

The FDA’s FY2024 Pharmaceutical Quality Report identified endotoxin contamination in facilities using non-validated purified water systems. Endotoxins are heat-stable bacterial by-products that are not removed by routine sterilization. Once they enter a product, the batch is typically rejected and may require investigation and disposal.

Water system failures don’t give you a heads-up. They quietly build up in dead legs, stagnant lines, and biofilm colonies growing inside unvalidated piping. The infrastructure design choices made during facility planning determine if these risks are controlled by design or found during an FDA inspection.

How Poor Infrastructure Drives Drug Recalls

The numbers speak for themselves. Sterility failures have consistently been among the leading causes of FDA-regulated pharmaceutical product recalls. These are not test failures, primarily. These are failures of the manufacturing environment, where a poor physical plant can allow contamination to reach a finished product.

CGMP deficiencies were responsible for approximately 50% of all drug recalls during the period of FY2020 to FY2023. That number declined in FY2024 but was still at 24%, still meaning hundreds of products were removed from shelves.

CGMP deficiencies caused more than half of all drug recalls in 2023. Thirteen percent of all recalls during the period studied were from one manufacturer that could not sustain CGMP requirements. Poor infrastructure not only leads to isolated failures. It can structurally compromise the entire site’s ability to manufacture compliant products.

The Turnkey Gap: Why Infrastructure Problems Start at the Design Stage

Many facility-related compliance issues originate during the design and planning stages.

The downstream effects are predictable when a pharmaceutical company constructs or expands a facility without qualified engineering oversight. Rooms are sized for convenience, not for classified environmental control. No drainage gradients are considered. Material flows are not mapped to contamination control logic. HVAC systems are sometimes specified without adequate consideration of ISO 14644 cleanroom standards or GMP zoning requirements.

By the time regulatory inspectors evaluate the facility, correcting these issues is often expensive and disruptive. Many times, it is much more expensive to retrofit a contamination control layout into an operating facility than to build it right the first time.

This is the power of pharmaceutical infrastructure solutions. A company with both pharmaceutical regulatory and engineering execution expertise can design contamination out of a facility from the outset rather than investigating it after production begins.

Pharma Access is a turnkey pharmaceutical engineering consultancy that supports pharmaceutical companies during the facility design phase to develop compliant, efficient, and quality-focused manufacturing environments Their approach, called “Engicution,” fuses engineering design with precision execution across disciplines from HVAC, cleanroom design, piping, utility systems, MEP, automation, and civil-structural work. They have over 24 years of experience and 120+ projects in 18 countries. They have worked on facilities for the following product categories: biotech, sterile manufacturing, oral solid dosage, oral liquid dosage, and API.

What Good Pharma Infrastructure Solutions Actually Look Like

What Good Pharma Infrastructure Solutions Actually Look Like

Effective pharmaceutical infrastructure planning is not about spending more—it is about investing appropriately, at the right stage, and with the right expertise.

This is what good infrastructure planning means:

  • Facility layout and flow design – Track personnel, material, waste, and product flows to avoid cross-contamination from the ground up
  • Cleanroom design & classification — Rooms designed to meet ISO 14644 requirements with correct air change rates, pressure cascades, and surface specifications
  • HVAC system design and qualification — Full IQ/OQ/PQ lifecycle planning built into the design phase, not tacked on later
  • Systems for purified water and WFI – Loop design that eliminates dead legs and supports validated sanitization cycles
  • Utilities design – Compressed air, nitrogen, steam, and process gases validated with appropriate monitoring
  • Modular construction options – Pre-engineered, GMP-compliant modules that reduce construction time without sacrificing compliance

Pharma Access provides consultancy services for pharma procurement consulting, including selection and supply of process equipment and machinery specific to the dosage form, regulatory environment, and production volume. If equipment procurement decisions are made incorrectly at an early stage, organizations may either under-specify operational requirements or overextend project budgets. Both create operational and compliance issues.”

The Real Cost of Getting Infrastructure Wrong

A pharmaceutical company that compromises on facility infrastructure does not simply risk a single batch.

Repeated GMP failures can lead to FDA consent decrees and other significant enforcement actions. The average enforcement period under a consent decree takes several years. In that period, companies might be barred from making or bringing drugs into regulated markets. The commercial impact of losing market access for an extended period can far exceed the investment required for compliant facility design and infrastructure.

There are patient consequences beyond regulatory consequences. Contaminated pharmaceutical products can result in serious infections, adverse events, and, in severe cases, patient fatalities. Subpotent drugs result in undertreatment of patients. Products that do not meet potency specifications can also cause significant patient harm. These results can be blamed on poorly designed, constructed, or maintained buildings, pipes, air systems, and water loops.

Next Steps for Pharma Companies Building or Upgrading Facilities

Facility infrastructure is the basis for new pharmaceutical facility planning, for expansion of an existing facility, and for evaluation of the compliance readiness of an older site.

Before you move on, ask yourself these questions:

  • Has the facility layout been reviewed by a pharma-qualified engineer on contamination control logic?
  • Is the HVAC engineered to cGMP and ISO 14644 with a full qualification plan?
  • Are water systems designed to eliminate dead legs and validate sanitization?
  • Has the utility system been mapped to the regulatory requirements for the dosage forms you are manufacturing?
  • Is a Commissioning, Qualification, and Validation (CQV) plan incorporated into the construction schedule?
  • These are questions that teams with pharmaceutical engineering expertise typically address before construction begins. Organizations that overlook these considerations frequently encounter them later during regulatory inspections or qualification activities.

Pharma Access is based in Andheri West, Mumbai, and provides services from facility planning to commissioning and validation, including engineering design, procurement, construction, and CQV under one coordinated engagement. Their team of 70 engineering personnel and 12 subject matter specialists, each with a focus on a specific discipline, injects regulatory knowledge into the design phase, not the compliance remediation phase.

Frequently Asked Questions

1. How does poor facility design directly affect pharmaceutical product quality?

Poor facility design creates conditions where contamination, cross-contamination, or environmental instability can reach the product. Inadequate air pressure between rooms, improper drainage, or non-validated water systems all create pathways for microbial or particulate contamination to enter finished drugs.

2. What is the most common infrastructure-related reason for FDA 483 observations?

Facility design and construction requirements are defined under 21 CFR 211.42 and remain among the most frequently cited areas during FDA inspections. In addition to this, section 211.113 for microbiological contamination control is also commonly seen. This is often the result of poor design or maintenance of HVAC and environmental control systems.

3. Why does HVAC matter so much in pharmaceutical manufacturing?

Pharmaceutical cleanroom HVAC is a validated manufacturing system, not a building utility. It regulates the number of air changes, pressure differences, temperature, humidity, and particles. Failure of any of these parameters can introduce contamination into a classified manufacturing environment and directly compromise product sterility or purity.

4. What is pharma procurement consulting, and when do you need it?

Pharma procurement consulting helps pharma companies define, evaluate, and source the right process equipment and machinery for their specific dosage form and regulatory requirements. You need it when designing a new facility, scaling production, or replacing aging equipment to avoid under-specification, vendor mismatches, or non-compliant equipment selections.

5. What is a pharma turnkey project, and how does it differ from standard construction?

A pharma turnkey project includes all aspects of delivering pharmaceutical facilities, such as engineering design, equipment procurement, civil & structural construction, HVAC & utilities installation, commissioning, qualification, and validation (CQV). The pharma turnkey approach is unlike standard construction in that it applies all GMP compliance requirements from the design stage all the way through handover, so the facility is ready to manufacture from day one.

Posted on

How Automation Helps Pharma Manufacturers Improve Production Efficiency

Automation Helps Pharma Manufacturers Improve Production Efficiency

A tablet press that runs at 400,000 units an hour means nothing if the batch fails the quality check. A continuous filling line still wastes money if it needs continuous manual intervention to keep it in spec. Pharma manufacturing has always been about precision, not speed. Automation enables manufacturers to achieve both precision and productivity while maintaining compliance.

This article explores the reality of how pharma manufacturing automation works, what tangible improvements it provides in production output and product quality, and what facility design decisions will make or break an automation project.

What Pharma Manufacturing Automation Actually Means

What Pharma Manufacturing Automation Actually Means

The term is used rather loosely. It’s a robotic arm on a packaging line in some conversations. In other cases, it means a fully integrated manufacturing execution system (MES) that links process equipment, quality testing, environmental monitoring, and batch documentation into a single data environment.

Here is the clearer definition: 

Pharma manufacturing automation is the use of controlled, mechanized, electronic, and software systems to perform manufacturing tasks with reduced  or no human intervention while producing the documentation necessary for regulatory compliance.

The last part is important. Automation in pharmaceutical manufacturing is more than a production tool. This is a compliance tool. FDA 21 CFR Part 11 establishes the criteria under which electronic records and electronic signatures can be used in place of paper-based records in a GMP environment. If any automated system deployed in a regulated pharma facility does not meet these requirements, it creates more regulatory problems than it solves.

Where Automation Creates the Biggest Gains

Batch Record Automation and Electronic Batch Records (EBR)

One of the biggest sources of error in pharmaceutical manufacturing is manual batch records. Batch failures and regulatory findings are the result of transcription errors, missing entries, incomplete logbooks, and illegible handwriting.

Electronic batch records use validated software systems, rather than paper, to capture process data in real time. Every step in a manufacturing process, from weighing raw materials to in-process checks to final release testing, is automatically recorded as it occurs. The system flags deviations immediately instead of waiting for a manual review at the end of a shift.

This results in less human error, faster batch release, and a complete audit trail that regulators can review during inspections. The FDA has long supported the use of electronic records in manufacturing, and electronic batch records are a key component of the agency’s guidance on pharmaceutical quality systems.

Process Analytical Technology (PAT) and Real-Time Monitoring

Process Analytical Technology (PAT) and Real-Time Monitoring

In traditional pharmaceutical manufacturing, samples are tested at the end of a batch. By the time a result comes back showing the product is out of spec, the entire batch may be rejected or need to be reprocessed.

PAT changes this model. Process analytical technology is the use of sensors in the manufacturing process itself to measure critical quality attributes in real-time. For example, NIR spectroscopy can be used to monitor the moisture content of granules during drying without sampling or process interruption. Inline viscosity measurement can follow a liquid formulation through a mixing step and alert operators if the product goes out of validated parameters.

The FDA issued its PAT guidance in 2004, describing PAT as a means to incorporate quality into manufacturing rather than test for quality at the end.

The use of PAT in combination with an automated feedback control allows the manufacturing system to self-correct. It compensates for drifts in the drying temperature. If blend uniformity is below the threshold, the blending step is extended automatically. These are not manual interventions, but automated process controls within validated ranges.

Read More: Pharmaceutical Facility Design and Construction

Automated Filling and Packaging Lines

Automated Filling and Packaging Lines

Aseptic filling is a contamination-sensitive operation in pharmaceutical production and is of utmost importance in sterile injectable manufacturing. There is a risk of contamination from human intervention in a cleanroom environment each time an operator enters a classified zone.

Automated filling lines with isolator technology or restricted access barrier systems (RABS) maintain a physical barrier between operators and the fill zone. Robotic systems are used for vial placement, filling, stoppering, and capping. This reduces contamination events directly and supports the contamination control strategies (CCS) emphasized under the revised EU GMP Annex 1.

Vision inspection systems replace manual visual inspection of fill volume, label placement, cap torque, and package integrity on packaging lines. These systems operate at line speed and provide objective, documented inspection records rather than subjective operator judgments.

Warehouse and Material Handling Automation

Warehouse and Material Handling Automation

Raw material management in a pharmaceutical facility is not just a logistics activity; it is a compliance activity. Materials must be  quarantined, sampled, tested, released, weighed, and dispensed with full traceability. Material identification or weighing errors can taint a batch or lead to a costly investigation.

Automated warehouse systems such as barcode and RFID-based inventory management, automated guided vehicles (AGVs), and dispensing systems with integrated label verification help to reduce the probability of the wrong material or the wrong quantity arriving at a manufacturing area. When these systems are integrated with the MES, every material movement is automatically included in the electronic batch record.

The Facility Design Connection

What many manufacturers miss is that automation is most effective when the facility is built with automation in mind. It is technically possible to construct a sophisticated automation system in a facility designed for manual operations, but it causes problems.

Let’s take it apart. A room must be built around a fully automated filling line: specific dimensions for the equipment footprint, ceiling heights to accommodate HEPA filter banks above the fill zone, conduit routing for control cables, utility connections at precise locations, and personnel access routes that do not cross the aseptic core. If the room were not designed with these requirements, the automation setup would be an expensive engineering hack.

Automation planning is included in the engineering design services of pharmaceutical facilities from the very beginning of the design At Pharma Access, this integrated approach is reflected in the Engicution methodology, where engineering design, automation planning, and project execution are developed together rather than as separate activities. . That is, not sequentially but in collaboration between process engineers, automation engineers, and facility designers. The design phase defines the architecture of the automation system (including PLC selection, SCADA layout, MES integration, and network topology) so that the facility is built to support it.

This thinking is central to what the team calls “Engicution” at Pharma Access—a combination of engineering and execution as one discipline that integrates facility design, automation planning, and project delivery from the outset. . When pharma turnkey project consultants in India and globally design and build a facility as a single integrated scope, automation needs to drive construction decisions, not the other way around.

Safety in Pharmaceutical Facility Design and Automation

Automation is also changing the safety equation in pharma manufacturing. And here’s why this matters directly.

Occupational exposure risks to production workers are present with many pharmaceutical products, including cytotoxic oncology drugs, hormones, and highly potent APIs (HPAPIs). Manual handling of these materials still presents residual risk, even with personal protective equipment.

Automated closed systems remove the worker from direct contact with hazardous materials. Robotic dispensing systems, automated weighing stations, and sealed transfer lines between process vessels minimizes operator exposure. Safety in pharmaceutical facility design is not a separate workstream from automation planning; it is the same conversation.

The National Institute for Occupational Safety and Health (NIOSH) guidance on occupational exposure to hazardous drugs supports the use of engineering controls (including automated closed systems) as the primary protective measure over administrative controls and personal protective equipment.

What a Phased Automation Approach Looks Like

Not every manufacturer can afford or needs full automation from day one. Facilities can develop automation capability over time through a phased approach, without impacting current production operations.

A practical series:

  1. Start with electronic batch records.” Substitute paper batch records with a validated EBR system. This delivers immediate compliance benefits and builds the data infrastructure upon which more sophisticated automation depends.
  2. Add automated environment monitoring. Replace manual particulate, temperature, and humidity sampling with continuous monitoring systems that report data directly to quality systems.
  3. Implement inline process monitoring (PAT). Start with installing sensors in the process steps that are the riskiest or most valuable, where the real-time data can impact the outcome of the batch the most.
  4. Automate the handling and dispensing of materials. Integrate warehouse and dispensing systems with the MES to automatically build material traceability into the electronic record.
  5. Move into robotic or automated fill-finish. This step provides the greatest reduction in contamination risk for sterile products, and generally, the investment is justified in reduced batch failure rates.

Each phase needs to go through the same qualification process as any other GMP system installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) with documentation to support regulatory submissions. 

Choosing the Right Partner for Pharma Automation Projects

Pharmaceutical manufacturing automation is not a product purchased from a catalog. It is a system that must be designed, built, validated, and maintained within a cGMP manufacturing environment.

The best projects are those where process engineering, automation engineering, and facility design are brought together as one well-organized team. When these are siloed, the gaps between them create integration problems that are costly to address post-commissioning.

Pharma Access provides engineering design services for pharmaceutical facilities that include automation planning in the base design scope. With over 120 projects across 18+ countries and facilities ranging from oral solid dosage to biotech and sterile injectables, the team understands that every plant has unique automation requirements that must align with the product, regulatory market, and production model.

The goal is always a facility where equipment, automation layer, and quality systems work hand in hand from day one without major corrections after commissioning.

FAQs 

1. What is pharma manufacturing automation, and why does it matter for compliance?

Pharma manufacturing automation involves mechanical, electronic, and software systems to execute manufacturing steps and collect records needed for GMP with minimal human intervention. This is important for compliance as automated systems, when validated correctly, generate documentation that is more consistent and complete than manual processes, thereby reducing the risk of regulatory findings during inspections.

2. How does automated batch record software differ from regular manufacturing software?

EBR software is specifically validated for use in GMP environments under 21 CFR Part 11 or equivalent regulations. It records process data in real time, enforces step sequences, prevents unauthorized changes, and maintains a complete audit trail. Standard manufacturing or ERP software doesn’t meet these requirements without additional validation.

3. Can existing pharmaceutical facilities adopt automation without a full rebuild?

Yes, but the scope of what is possible is dependent on the existing facility layout, utility infrastructure, and equipment. Most current facilities can implement a phased approach, beginning with electronic records and environmental monitoring. Robotic filling is typically fully automated and requires space modifications or new construction to accommodate equipment footprints, utility connections, and environmental control requirements.

4. What is Process Analytical Technology (PAT), and how does it help production?

PAT uses sensors directly embedded in the manufacturing process to measure product quality attributes in real time, such as moisture content, particle size, or blend uniformity. This enables the process to be monitored and adjusted during production, rather than waiting for end-of-batch testing, which reduces batch failures and accelerates release timelines.

5. How does safety in pharmaceutical facility design connect to automation decisions?

Closed automated systems reduce worker exposure by removing the need for manual handling of hazardous substances, for example, in facilities that handle hazardous materials such as cytotoxic drugs or highly potent APIs. Coordinating automation decisions with safety engineering during the facility design stage is significantly more effective and cost-efficient. Adding closed systems after construction is much more expensive than including them at the outset.

Posted on

Trends and Challenges in Biopharmaceutical Facility Design

Trends and Challenges in Biopharmaceutical Facility Design

The biopharmaceutical manufacturing arena has evolved more in the last decade than in the previous three decades combined. Stricter global regulations and looming timelines are forcing facility designers, engineers, and project teams to reevaluate nearly every assumption they once took for granted, and emerging drug modalities are adding to the complexity.

This article examines the current state of biopharmaceutical facility design, what is driving the next wave of projects, and the real obstacles teams face when planning, building, and qualifying these facilities.

Why Biopharmaceutical Facility Design Is Under More Pressure Than Ever

Biologics are in increasing demand. Cell and gene therapies, monoclonal antibodies, antibody-drug conjugates (ADCs), and mRNA-based products are now making up a growing portion of clinical pipelines globally.

Here’s why this is important for facility design: Each of these product types has its own contamination risk profile, contained environment needs, and regulatory classification. In most cases, converting a monoclonal antibody facility into a cell therapy manufacturing facility requires significant redesign due to differences in process, containment, and operational requirements. If you get the design wrong from the beginning, you create downstream problems that cost a lot more to fix than they would have cost to prevent.

The U.S. FDA guidance on Current Good Manufacturing Practice (cGMP) for biologics and EMA’s Annex 1 requirements for sterile manufacturing (updated in 2022) make it clear that regulators expect facility design to be part of the quality system, not simply a construction exercise.

Cleanroom biotech production facility inspection

Key Trends Shaping Biopharmaceutical Facility Design Today

1. Modular and Prefabricated Facility Concepts

Traditional stick-builds take three to five years to complete. That timeline is a huge problem for a company racing to get a biologic from Phase III trials to commercial manufacturing.

Modular construction can fix this. Prefabricated cleanroom modules, utility skids, and process equipment assemblies are manufactured in controlled environments off-site and installed on-site in a fraction of the time. This also reduces construction variability, a direct contributor to cGMP compliance risk.

The rise of modular facility models represents a real shift in the way pharma companies view speed-to-market without sacrificing quality or regulatory standing.

2. Flexible Multi-Product Facility Layouts

This approach made sense when demand patterns were stable and blockbuster biologics remained in production for decades. That model is increasingly being replaced by more flexible manufacturing strategies. Manufacturers now want facilities that can handle two or three products, sometimes across modalities, without full shutdowns between campaigns.

To understand this shift, consider the operational requirements. Flexible facility design means the ability to change over from one campaign to the next, closed-system processing, and equipment designed for clean-in-place and sterilize-in-place (CIP/SIP) cycles without dismantling the line.

To do this right requires early design decisions on segregation strategy, airlock placement, HVAC zoning, and cross-contamination controls. These are not afterthoughts; they are design constraints that determine the entire facility layout.

3. Closed Processing Systems and Containment

Biological products, especially those derived from living organisms or employing viral vectors, have to be strictly contained. Manufacturers need to convince regulators that their containment strategy will not allow release to the environment and will protect operators.

Closed processing systems, in which product pathways are isolated from the manufacturing environment, are becoming the rule rather than the exception. This change affects biosafety cabinet selection, transfer port design, design of single-use assemblies, and waste deactivation systems.

WHO GMP design guidelines for biological products emphasize the importance of documented containment strategies, contamination control measures, and risk-based facility design as part of an effective quality system.

4. Single-Use Technology Integration

Single-use bioreactors, bags, tubing sets, and filters have revolutionized upstream and downstream processing. They remove the cleaning and validation of stainless steel equipment from batch to batch, reducing changeover time and the risk of cross-contamination.

The problem in designing the facility is that single-use systems need careful planning for waste management. Running a 2,000-liter single-use bioreactor produces a lot of plastic waste. Waste segregation, deactivation, and disposal pathways must be incorporated into the facility design from day one. This consideration is often overlooked during early-stage facility planning.

5. Pharma 4.0 and Continuous Monitoring

Real-time monitoring systems and more advanced automation are being adopted in newer facilities using Process Analytical Technology (PAT) frameworks. While still emerging in biologics manufacturing, continuous processing approaches are gaining interest in selected upstream and downstream bioprocessing applications.

This results in specific design requirements: sensor placement, data infrastructure, validated software systems, and the integration between the manufacturing execution system (MES) and quality management systems. These considerations influence not only software selection but also broader engineering design requirements.

The Biggest Challenges in Biopharmaceutical Facility Design

The Biggest Challenges in Biopharmaceutical Facility Design

Regulatory Variability Across Markets

A facility designed for FDA approval may need substantial documentation rework to meet the requirements of EMA, PMDA (Japan), or CDSCO (India). The ICH guidelines give us a common language, but in practice, each agency has its own interpretation.

Next steps for any project team: Map target markets early in design. Facility design and regulatory strategy should be developed together from the earliest project stages.

HVAC and Cleanroom Design Complexity

Biopharmaceutical facility HVAC systems are more than just temperature and humidity. They govern the rate of air change, differential room pressure, particle counts, and levels of microbial contamination. The updated requirements in Annex 1 have raised the bar on contamination control strategies by requiring a formal Contamination Control Strategy (CCS) document that ties HVAC design to product risk.

Designing an HVAC system to be compliant with ISO 14644 cleanroom classifications and also meet cGMP requirements for pressure cascades and segregation between different classified areas requires specialized engineering knowledge and careful computational fluid dynamics (CFD) modeling.

HVAC and Cleanroom Design Complexity

Skilled Workforce Shortages for Specialized Facilities

GMP manufacturing knowledge and knowledge of the specific biology of living cell products are required of engineers working in cell and gene therapy facilities. This is a rare combination. Project teams often find that there is a shortage of qualified validation engineers, commissioning specialists, and quality system experts.

And in fact, a talent shortage can be just as much of a bottleneck to a facility project as construction delays. Workforce planning should begin during the design phase, not after construction is complete.

Balancing Speed with GMP Compliance

Investors and boards want facilities up and running fast. Regulators want documentation, validation, and quality systems that take time to build correctly. These two pressures are constantly pulling in different directions.

Shortcuts in design documentation, equipment qualification, or utilities validation will cost more in the long run. Pharmaceutical industry facilities have a long history of passing construction inspections but failing pre-approval inspections because of a lack of a complete design-to-commissioning documentation trail.

Sustainability Requirements

The carbon footprint of a biopharmaceutical facility includes water-for-injection (WFI) generation, clean steam systems, and HVAC, as well as energy-intensive processes. Regulatory agencies are starting to require environmental impact assessments, and large pharma companies are developing internal sustainability goals that drive their vendor and facility selection.

Facility designers now have to think about energy recovery systems, low-GWP refrigerants for HVAC, and water recycling strategies in addition to traditional GMP requirements.

What Good Biopharmaceutical Facility Design Actually Looks Like

Good design is a product of a clear product brief. What product is being manufactured? What are target markets? What is the anticipated batch size and campaign frequency? What is the 10-year production outlook?

From those responses, a design team lays out the process flow, which defines the room adjacency diagram, which then feeds the HVAC design, utilities matrix, and equipment list. The order is important. Issues are expected when teams attempt to retrofit a product process into a building that was not designed for it.

This approach is known at Pharma Access as “Engicution,” an integration of engineering thinking with execution precision right from the earliest project stage all the way through commissioning, qualification, and validation (CQV). Our teams have delivered turnkey biopharmaceutical facilities across more than 18 countries, enabling design decisions that reflect regulatory realities across multiple markets rather than a single jurisdiction.

At this level, biotech turnkey consulting means one team owns the design, procurement, construction, and validation process. Such continuity reduces information loss between project phases, one of the most prevalent sources of compliance gaps in complex facility projects.

How Indian Pharma Consultancy Is Shaping Global Facility Projects

India has emerged as a trusted source for pharma consultancy services for biopharmaceutical projects across the world. The country’s established generics industry and its long relationship with FDA, WHO, and other global regulatory standards have created engineering and consultancy firms with real global experience.

Mumbai’s pharma consultancy in particular caters to a cluster of Indian and multinational pharma companies with manufacturing ambitions in Asia, Africa, and the Middle East. Companies working from this base frequently have experience across regulatory jurisdictions from the CDSCO to the EMA, providing a practical cross-market design perspective that single-market consultants cannot easily match.

FAQs

1. What is the difference between a GMP facility and a biopharmaceutical facility?

A GMP facility is a place where current good manufacturing practice (CGMP) regulations are followed. A biopharmaceutical manufacturing facility is a unique kind of GMP facility that is designed to manufacture biological products such as vaccines, antibodies, or cell therapies. These facilities require special containment, cleanroom design, and validation requirements beyond those in standard pharmaceutical manufacturing.

2. How long does it take to design and build a biopharmaceutical facility?

A typical biopharmaceutical facility can expect to spend three to five years from concept to the approval of the first batch. In good conditions, modular facility approaches can reduce this to two to three years. Timing depends on regulatory market targets, product type, site complexity, and readiness of the design and engineering team.

3. What cleanroom classification do biopharmaceutical facilities need?

Most aseptic biopharmaceutical manufacturing processes require Grade A (ISO Class 5 equivalent) conditions at critical processing points, supported by Grade B environments for aseptic operations. Grade C and Grade D areas may be used for less critical processing steps depending on the process design and risk assessment. The exact classification depends on the product, process, and regulatory authority requirements of the target market.

4. What is commissioning, qualification, and validation (CQV) in pharma facility design?

CQV is the process of assuring that a facility and its equipment perform as designed and meet GMP requirements. Commissioning checks that systems are operating to engineering specifications. Qualification (IQ, OQ, PQ) tests that the equipment fulfills user requirements. “Validation” means that the manufacturing process consistently produces a product that satisfies quality specifications. All three must be in place before a facility can gain regulatory approval.

5. Why should I work with a turnkey biopharmaceutical facility consultant rather than managing separate design and construction firms?

A turnkey consultant is responsible for the whole project scope. One team designs, procures, builds, and validates, so there is less information loss between stages, clearer documentation trails, and one point of accountability for meeting schedule and regulatory requirements. Fragmentation in project management is one of the most common drivers of cost overruns and regulatory delays in complex biopharmaceutical projects.